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Abstract 
Chronic obstructive pulmonary disease (COPD) is a multifactorial and systemic 
disease driven by inflammation and oxidative stress, predominantly caused by 
smoking, but exacerbated by infection and pollution. Current therapies aim to treat 
specific aspects of the disease and/or symptoms rather than the disease as a whole. 
 
Vitamin D, more commonly known for its importance in calcium and phosphorus 
homeostasis, has now been established as an important immunomodulatory agent. 
Recent studies have shown vitamin D deficiency to be associated with reduced lung 
function and COPD disease severity. Equally vitamin D has been shown to modulate 
a number of inflammatory mediators which are important in COPD pathology. 
Together, these suggest that vitamin D may be beneficial in COPD. Airway epithelial 
cells play a central role in COPD pathogenesis and have been shown to 
constitutively activate vitamin D. This study investigated the effects of vitamin D on 
inflammation and oxidative stress in human airway epithelial cells, crucially on 
mediators important in COPD pathology and also investigated the potential 
mechanisms involved in the action of vitamin D.  
 
Three different human airway epithelial cell lines A549, NCI-H292, 16HBE14o- and 
primary human small airway epithelial cells were shown to express similar 
inflammatory mediators, with the 16HBE14o- cells shown to be a useful model of 
primary cells. Vitamin D significantly modulated IL-6 mRNA and protein expression 
in the primary cells and reduced MUC5AC mRNA and protein expression in the 
mucous producing NCI-H292 cells. Interestingly, vitamin D treatment gave a 
biphasic effect on induction of inflammatory mediators by TNFα in the NCI-H292 
cells. Vitamin D also modulated the induction of oxidative stress, antioxidant gene 
expression and Nrf2 protein expression in the NCI-H292 cells. 
 
This data emphasises the complexity of vitamin D modulation of inflammatory 
mediators and oxidative stress in airway epithelial cells and provides new novel 
avenues of future study.  
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Chapter 1: Introduction
 22 
1.1 Chronic Obstructive Pulmonary Disease (COPD) 
COPD is defined as a progressive airflow obstruction which is not fully reversible, 
with an abnormal inflammatory response (1). It is estimated that 210 million people 
have COPD worldwide and it is predicted to be the third leading cause of death by 
2020 (2).  In the UK, the prevalence is 1% increasing to 10% in males over the age of 
75 (World Health Organisation (WHO)). 90% of COPD related deaths occur in low-
middle income countries due to the reduced accessibility to treatments and 
preventative measures.  
 
1.1.1 Aetiology 
More than 90% of all COPD cases are associated with smoking (2). However, only 
15% of smokers develop COPD, suggesting that there are differences in an 
individual’s susceptibility to the disease. Although an inflammatory response to 
cigarette smoke is present in all smokers, in some the inflammation persists on 
smoking cessation (3). The differences in an individual’s susceptibility to COPD and 
ability to modulate responses to cigarette smoke is key to understanding the vast 
spectrum of airway disease present in COPD.  Air pollution is another contributor to 
COPD development including occupational dust, chemicals and the indoor use of 
solid fuel for cooking and heating in low-income countries (WHO). Genetic factors 
can also influence COPD, including variability in genes involved in protease 
production, response to cigarette smoke and mucociliary clearance (4). 
 
1.1.2 Signs and Symptoms 
The main symptoms of patients with COPD are breathlessness, a chronic cough and 
an abnormal sputum / excessive mucous production (WHO). Clinically, the forced 
expiratory volume in one second (FEV1) measured by spirometry, is an indicator of 
the degree of airway obstruction and a decline in FEV1 is correlated with disease 
severity. 
 
1.1.3 Pathology 
COPD encompasses a range of different disease pathologies. The terms emphysema 
and chronic bronchitis are no longer used but are included in the diagnosis of COPD 
(WHO)(1). Emphysema, chronic bronchitis with airway obstruction, and small airway 
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disease are the distinct phenotypes of COPD but most patients show overlapping 
pathologies (5). COPD is characterised by airflow obstruction with excessive mucous 
secretion, and destruction of airspaces with loss of lung elastic recoil, chronic 
inflammation and tissue remodelling without fibrosis (1, 3, 6). Remodelling causes the 
airway wall to thicken reducing the elasticity and the alveolar attachments are 
disrupted from the membrane leading to alveolar collapse. These pathologies 
collectively lead to a reduction in FEV1. 
 
1.1.4 Systemic effects 
The complexity of COPD is not restricted to the respiratory system; COPD is a 
systemic disease involving skeletal muscle and the cardiovascular system with 
weight loss and muscle weakness all associated with an increased risk of mortality 
(6, 7). Malnutrition is common in patients with COPD, affecting 50% of patients with 
advanced stage disease (7). The cause of weight loss is a matter of debate with a 
high metabolic rate thought to play a major role. There are several proposed 
mechanisms contributing to an increased metabolic rate. These include; increased 
oxygen consumption by respiratory muscles to overcome obstruction, the 
medications given to patients, and inflammatory mediators. Depletion of muscle 
mass in COPD is associated with mitochondrial abnormalities and loss of contractile 
proteins with malfunction of any remaining muscle (7).  Alongside COPD, cigarette 
smoke is associated with a 50% increased risk of heart failure so it is not surprising 
that heart disease is a co-morbidity of COPD and vice versa. With COPD 
characterised by a low grade systemic inflammation, this can contribute to the 
progression of atherosclerosis and cardiovascular events (8). 
 
1.1.5 Exacerbations 
An exacerbation is defined as an acute and sustained worsening of a patient’s 
symptoms from their usual state beyond the normal day to day variation (9). 
Exacerbations of COPD play a major role in the morbidity, mortality and severity of 
the disease. Acute exacerbations are the most frequent cause of hospital admission 
and death amongst patients with chronic lung disease and are a major burden on 
the health service (10). Although infection is the major cause of exacerbations, air 
pollution can also contribute. The prominent bacteria found in COPD exacerbations 
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are Haemophilus influenza, Moraxella catarrhalis, Streptococcus pneumoniae and 
Pseudomonas aeruginosa which is the most frequent bacterial pathogen in severe 
COPD and elicits the greatest inflammation giving accelerated lung function decline 
(10-14). The rhinovirus is the dominant viral pathogen in acute exacerbations (11). Both 
viral and bacterial exacerbations increase inflammation with cell infiltration and 
cytokine production, leading to progression of the disease.  
 
1.1.6  Pathogenesis 
The pathogenesis of COPD involves many different processes, including cell 
infiltration, alveolar cell apoptosis, extracellular matrix proteolysis, inflammation, 
oxidative stress and epigenetic modulation (6), all of which will be discussed in the 
next sections. 
 
1.1.6.1 Cell infiltration 
COPD is characterised by a neutrophil and macrophage-induced inflammation that 
develops over many years (2). There is a chronic inflammatory cell infiltration of the 
bronchial wall, goblet cell hyperplasia and metaplasia and a decrease in the number 
and length of the cilia, reducing mucocilliary clearance causing airway obstruction. 
A recent theory is that bronchiole vascular remodelling is one of the first steps 
leading to COPD pathology and is thought to involve the mobilisation of endothelial 
progenitor cells (EPCs) into the lung from the bone marrow to produce new blood 
vessels (15). These new vessels are the means by which cytokines and chemokines 
interact with the lung epithelium and immune cells. Recent work suggests that 
cigarette smoke-induced angiogenesis and leukocyte trafficking may be important 
for the recruitment of inflammatory cells to the airways (16), with smokers lungs 
having increased numbers of neutrophils, lymphocytes and macrophages (6).  
 
Cigarette smoke induces increased levels of circulating neutrophils in the lungs 
which are sequestered in the lung capillaries (3) through the rolling of neutrophils on 
endothelial cells. Neutrophils are an abundant cell type found in both the 
bronchoalveolar lavage fluid (BAL) and sputum samples from patients with COPD (3). 
They are a prominent source of inflammatory mediators (3).  
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The healthy lung contains resident macrophages although in COPD it is the 
infiltrating inflammatory macrophages that are the main source of cytokines. 
Macrophages are activated by cigarette smoke and they are also increased in BAL 
fluid of COPD patients. The number of macrophages in the alveolar wall correlates 
with destruction, and in the airways correlates with the severity of obstruction 
providing evidence of the major role of macrophages in COPD pathophysiology (17). 
 
CD8 positive cells are the most abundant T cell subset in COPD. They are increased 
in the epithelium and their numbers correlate with reduced lung function. They also 
release a number of different inflammatory mediators (17).  
  
The airway epithelium is now being recognised as an important contributor of a 
wide range of cytokines and chemokines that recruit both neutrophils and 
macrophages, which are important in the pathogenesis of COPD (17, 18). Primary 
small airway epithelial cells (SAEC) and normal human bronchial epithelial cells 
(NHBE) are the cell lines which are the closest models to in vivo lung however they 
are expensive and have a relatively short lifespan which means experimentally they 
are used infrequently shown by the small amount of literature with these cell lines 
studying lung inflammation. There are numerous lung epithelial cell lines used as 
model cell systems to study lung inflammation, most of which are derived from 
cancerous tissue. Although they may show different expression patterns than the 
primary cells, they provide an alternative in which to optimise experiments and give 
indications of what inflammatory mediators are produced by the airway epithelium. 
The A549 cell line is derived from a lung adenocarcinoma however they are used as 
a model of the alveolar epithelial type II cells and there is extensive literature on all 
aspects of this cell line including production of cytokines, mucins, matrix 
metalloproteinases and reactive oxygen species in response to different stimuli (19, 
20). NCI-H292 are a mucoepidermoid lung cancer cell lines which have been used 
amongst other things to study the effect of lipopolysaccharide on mucin production 
in airway epithelial cells (21). 16HBE14o- are a SV-40 transformed bronchial 
epithelial cell line which has been used widely to study epithelial barrier function 
and ion transport and shows similar characteristics to primary bronchial cells (22). 
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1.1.6.2 Cell death 
COPD patients have a greater number of apoptotic cells within their lung tissue 
including alveolar and bronchial epithelial cells and endothelial cells in the 
parenchyma (23). Cigarette smoke can directly induce necrosis in cells via caspase 
inhibition (24). Cells undergoing programmed cell death can be quickly removed by 
the surrounding milieu of cells, not only by professional phagocytes, but also 
fibroblasts, endothelial, epithelial, stromal and smooth muscle cells (23). However, in 
COPD this clearance of apoptotic cells is reduced. Surfactant proteins SF-A and D 
are also thought to be important in aiding the clearance of apoptotic cells and these 
are decreased in the lungs of smokers (23). 
 
1.1.6.3 Inflammation 
There is a cellular homeostatic balance between the production of pro and anti-
inflammatory mediators. In the lungs, cigarette smoke, oxidative stress and 
infections contribute to produce a pro-inflammatory profile. In lungs of smokers 
there is an increased production of  interleukins (IL-): IL-1β, IL-6, IL-8, IL-10, IL12p70 
and tumour necrosis factor alpha (TNFα) in breath condensates (6), some of which 
correspond to those that are increased in the sputum during exacerbations of 
COPD; IL-6, IL-1β, TNFα, chemokine ligand 1 (CXCL1), monocyte chemotactic protein 
1 (MCP-1), and IL-8. Clinical markers of the severity of COPD include; IL-6, IL-8, IL-10 
and TNFα with bronchial biopsies of COPD patients having an increased expression 
of IL-10 (3). Inflammation may also be responsible for systemic manifestations and 
co-morbidities of COPD such as muscle dysfunction, cardiovascular disease and 
osteoporosis (25) with elevated levels of systemic pro-inflammatory cytokines such 
as TNFα and IL-6 observed in COPD patients (7).  
 
IL-6 is a multifunctional cytokine which plays a central role in host defence due to 
its range of immune activities and ability to induce the acute phase response. It is 
induced in infection, trauma or other stress when it contributes to inflammation by 
leukocytosis, thombocytosis, lymphocyte activation and acute phase protein 
synthesis (26). IL-6 can also activate pulmonary epithelial cells (3).   
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TNFα is elevated in bronchial biopsies, induced sputum and BAL fluid of COPD 
patients and is also significantly increased in the sputum during acute exacerbations 
(27). It is produced by a range of cell types including alveolar macrophages, 
neutrophils and epithelial cells after contact with cigarette smoke (27). TNFα 
stimulation of the pulmonary epithelium is a major contributor of acute lung injury 
(28). Using TNFα receptor knock out mice Churg et al (2004) showed that 60-70% of 
airway enlargement in COPD is dependent on TNFα. TNFα is also important for the 
production of matrix metalloproteinases (MMPs) although this process isn’t 
completely TNFα dependent (29). TNFα may also increase fibroblast proliferation, 
differentiation and extracellular matrix deposition as well as promoting MMP 
induction (30). TNFα can inhibit macrophage apoptotic cell uptake and therefore 
clearance of apoptotic cells from the lung (23), leading to further airway obstruction. 
 
IL-8 (also known as CXCL8) is a key contributor to COPD pathology as a neutrophil 
chemoattractant and is also an activator of immune responses. It is found in high 
concentrations in sputum and BAL fluid of patients with COPD (24) and can be 
produced by activated bronchial epithelial cells, macrophages and neutrophils in a 
mechanism of positive feedback (3). 
 
Leukotriene B4 (LTB4) is also a neutrophil chemoattractant and is secreted by 
alveolar macrophages and neutrophils (24). Leukocyte recruitment is an important 
step in tissue inflammation. Firm adhesion of neutrophils to endothelial cells is 
important for them to migrate to sites of inflammation and occurs via binding of 
neutrophil integrins to intercellular adhesion molecule -1 (ICAM-1) (31). In tracheal 
epithelial cells ICAM-1 can be induced by TNFα and IL-1β. In alveolar type 1 or 2 
cells it is also induced by hyperoxia or lipopolysaccaride (LPS) (32).  LPS is a structural 
component of the outer membrane of gram negative bacteria and can activate 
nuclear factor kappa B (NFκB) via signalling through toll like receptor 4 (TLR4) on 
the cell surface of numerous cell types, which is important in COPD exacerbations 
(33). The antimicrobial peptide cathelicidin LL-37 is produced by neutrophils, 
macrophages and respiratory epithelial cells on TLR4 activation, is increased in the 
sputum of patients with COPD and is suggested to be a biomarker of COPD 
progression (34). 
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In relation to airway remodelling, transforming growth factor beta 1 (TGFβ1) is 
increased in the small airways and alveolar epithelial cells in patients with COPD 
and participates in fibrotic processes in the smaller airways (24). Endothelin -1 is 
increased in COPD sputum and is important in pulmonary vascular remodelling. 
Genetic deletion of vascular endothelial growth factor (VEGF) causes airspace 
enlargement, and leads to alveolar apoptosis and COPD development in rats, 
suggesting that VEGF is an important contributor to the destructive processes (24, 35). 
 
 
1.1.6.3.1 – Signalling pathways activated by inflammation (Figure 1.2) 
1.1.6.3.1.1 NFκB  
Nuclear Factor kappa B (NFκB) is an ubiquitous transcription factor regulating a 
large number of genes involved in inflammation, growth, apoptosis and 
carcinogenesis (36). Patients with COPD have increased NFκB activation in 
macrophage and epithelial cells, and it is further activated during exacerbations (37). 
NFκB consists of a family of transcription factors, classically as a heterodimeric 
complex of p50 and p65/RelA subunits. In an unstimulated cell, NFκB is in the 
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cytoplasm bound to inhibitor of κB (IκB) which masks the nuclear localisation signal 
holding NFκB in the cytoplasm. Upon cell stimulation including cytokines, 
pathogens and oxidative stress, IκB is rapidly phosphorylated by inhibitor of κB 
kinase (IKK) targeting it for ubiquitination and subsequent degradation by the 26S 
proteasome, releasing NFκB to translocate to the nucleus and activate target genes 
(38). NFκB is a key transcription factor involved in the transcription of a wide number 
of inflammatory mediators including TNFα, interleukins, adhesion molecules, matrix 
metalloproteinases and oxidative stress such as hydrogen peroxide, all of which are 
important in COPD pathogenesis (1, 37). IκBα levels are significantly decreased whilst 
NFκB DNA binding significantly increased in healthy smokers and current smokers 
with moderate COPD compared to healthy non smokers (6). 
 
1.1.6.3.1.2 MAPK pathway 
The Mitogen Activated Protein Kinase (MAP kinase) signal transduction pathways 
are activated in COPD and play a key role in its pathogenesis (37). These pathways 
are activated by different stimuli and can activate the same or different 
phosphorylation cascades regulating a diverse range of cellular events.  
 
1.1.6.3.1.2.1 ERK 
The classical MAP kinase pathway is the Ras / extracellular signal regulated kinase 
(ERK) pathway. This is typically activated by mitogenic stimuli such as growth 
factors. Binding leads to tyrosine kinase receptor dimerisation and 
autophosphorylation activating Guanosine nucleotide Exchange Factors (GEF’s) 
activating the GTPase Ras recruiting and activating MAPKKK leading to 
phosphorylation of dual specificity MAPKK (MKKs or MEKs) which activate ERK1/2 
activating transcription factors implicated MMP-1 release, MUC5AC production and 
growth factors eg epidermal growth factor (EGF) release (39, 40). ERK1/2 is 
significantly elevated in airway and alveolar epithelial cells in patients with 
emphysema compared to controls (39). 
 
1.1.6.3.1.2.2 p38 MAPK 
The p38 MAPK family consists of four different isoforms expressed in different 
tissues, regulating and activating different kinases and phosphorylation cascades 
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causing diverse and opposing effects (37). The α isoform is expressed in airway 
smooth muscle, epithelial cells and immune cells and studies on COPD have focused 
on this isoform (37). p38 MAPK is activated in response to many inflammatory signals 
including inflammatory cytokines, smoking, infection and oxidative stress. p38 
MAPK activation is key in COPD and is correlated with the degree of lung function 
impairment and inflammation (37).  
 
1.1.6.3.1.2.3 JNK 
JNK is a stress-activated protein kinase that is activated by a wide range of cellular 
insults including ROS and inflammatory stimuli (41). JNK was first identified as the 
enzyme responsible for phosphorylation the N-terminus of c-Jun a component of 
the Activator Protein 1 (AP-1) transcription factor regulating expression of many 
physiological processes including cytokine and inflammatory gene expression (41). 
JNKs are protein kinases that phosphorylate target proteins such as transcription 
factors, adaptor proteins and cytoskeletal proteins. JNK1 and 2 are the relevant 
isoforms for respiratory disease (41). In a mouse model of chronic lung inflammation 
inhibition of JNK significantly inhibited TNFα, IL-4, IL-13 and CCL5 expression. The 
role of JNK in cell types central to respiratory disease is poorly understood (41). 
Activation of JNK has been shown to be involved in TNFα induced MMP-9 
expression in lung epithelial cells (42). 
 
There is also crosstalk between MAPK pathways for example ERK1/2 and JNK have 
been shown to activate NFκB signalling in airway epithelial cells (39). As multiple 
kinases and signalling pathways can activate airway inflammation, blocking one 
kinase may just lead to increased activity of another (37). 
 
1.1.6.3.1.3 PI3K 
PI3K Phosphatidylinositol 3-kinase (PI3K) is a family of proteins that catalyse the 
phosphorylation of phophoinositides and generate lipids that control a wide variety 
of intracellular signalling pathways. They play a crucial role in the expression and 
activation of inflammatory mediators, inflammatory cell recruitment, airway 
remodelling and corticosteroid insensitivity (43, 44). PI3K is important for macrophage 
and neutrophil activation and is also involved in leukocyte migration (45). It also 
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regulates MMP-9 expression (43). Abnormal PI3K activation in bronchial epithelium 
of smokers is an early event in the development of lung cancer (44).  
 
1.1.6.3.1.4 Rho Kinase 
Rho/Rho kinase signalling has emerged as a key regulatory pathway in several 
processes underlying airway inflammation in COPD including the trafficking of 
inflammatory cells and remodelling of the airway epithelium (46, 47). The Rho family 
of small GTPases are involved in regulating actin remodelling and adhesion 
important in inflammatory cell and airway epithelial cell migration (46). The G 
protein RhoA is the main upstream activator of Rho kinases (ROCK) and is highly 
expressed in airway smooth muscle and can be activated by a variety of G protein 
coupled receptors (GPCR) through interaction with GEFs. In addition, cytokines and 
ECM proteins have emerged as inducers of the Rho/Rho kinase signalling pathway 
(48).  
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1.1.6.4 Proteases 
In healthy individuals there is a balance between proteases and their inhibitors 
important for airway remodelling. However, in COPD proteases are increased and 
their inhibitors are decreased potentiating the destructive processes within the 
lungs (49). 
 
Anti alpha trypsin is an important anti-protease enzyme found in the serum which 
inhibits neutrophil elastase (4). α1 anti-trypsin deficiency is one of the genetic 
causes of COPD particularly in smokers, but only accounts for <1% of cases (24). 
Elastase breaks down extracellular matrix leading to lung damage and alveolar 
collapse and mice lacking this enzyme are protected from alveolar destruction 
induced from chronic cigarette smoke exposure (50). Proteinase 3 and Cathepsin G 
are other serine proteases with elastolytic activity found in neutrophils. Cathepsins 
B, K, L and S are cysteine proteases also with elastolytic activity and are elevated in 
lung macrophages in patients with COPD (3, 24). Secretory leukocyte protease 
inhibitor (SLPI) is secreted by airway epithelial cells and is an important inhibitor of 
neutrophil elastase (24, 51). Low concentrations of SLPI are associated with an 
increased risk of COPD exacerbations (51). 
 
Matrix metalloproteinases (MMPs) are a family of enzymes involved in the 
breakdown of a wide range of extracellular matrix components important for 
remodelling. This family of enzymes is produced by neutrophils, alveolar 
macrophages and airway epithelial cells (3, 24). MMP-12, also termed macrophage 
metalloelastase, can degrade elastin and therefore has implications in alveolar 
destruction. Neutrophil elastase and MMP-12 can cleave receptors on macrophages 
that are important for the recognition and clearance of apoptotic cells (23). MMP-12 
activity in patients with COPD has been directly associated with the extent of 
emphysema (52). Polymorphisms in MMP1 and MMP12 have been shown to reduce 
FEV1 (4) and patients with COPD have increased levels of neutrophil collagenase 
MMP-8 and gelatinase B MMP-9 (4). Patients with COPD also have increased levels 
of MMP-1 and MMP-9 in BAL fluid and BAL macrophages express more MMP-9 and 
MMP-1 than cells from control subjects (24). After smoking cessation for 3 months 
patients still had the presence of collagenase MMP-1 in the lungs suggesting that 
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cigarette smoke provides more long term changes in protease expression remaining 
long after smoking cessation (53). Higher levels of MMP-9 are found in the serum of 
patients with COPD than control patients and it is associated with the stage of 
COPD and may play a role in systemic inflammatory responses (54). MMP-9 and -12 
are current research targets for inhibitors to use for COPD therapy (55, 56). 
 
Natural inhibitors of MMPs within the body are tissue inhibitors of 
metalloproteinases (TIMPs). Polymorphisms in the TIMP2 gene are associated with 
COPD development (4). Both airway macrophages alone and those subjected to IL-
1β and LPS from smokers release more MMP-9 and TIMP-1 than age matched 
controls from non smokers (57).  During exacerbations of COPD, there is increased 
MMP-9 causing an imbalance between MMP-9/TIMP-1 in favour of destruction (58).  
 
1.1.6.5 Mucous hypersecretion 
Mucous hypersecretion is important in COPD pathology and can be caused from 
smoking, infection and inflammatory cells activating mucin transcription (3). The 
mucous layer normally plays a protective role in the airways against inhaled 
pathogens, toxins and other foreign particles by mucociliary clearance (59). However, 
abnormal mucous production and clearance contribute to COPD pathology with 
goblet cell hyperplasia and metaplasia. The major mucins of airway mucous 
secretions are MUC5AC and MUC5B, with MUC5AC being the secretion from the 
goblet cells on the epithelium and MUC5B from the submucosal glands (59, 60). 
 
1.1.6.6 Oxidative Stress 
Oxidative stress is thought to be one of the main driving forces behind COPD 
inflammation (1). The lung epithelium is constantly exposed to oxidants generated 
endogenously during respiration and also from activated infiltrating inflammatory 
cells and air pollution (5). In addition, inhaled cigarette smoke contains reactive 
oxygen species (ROS), reactive nitrogen species (RNS), and nitric oxide (NO) (61). 
Oxidative stress occurs when the oxidant burden is unable to be neutralised by 
resident antioxidants. Generation of ROS are directly associated with oxidative 
modification of proteins, lipids, carbohydrates and DNA. Oxidative stress can cause 
cell damage, cell necrosis, apoptosis, autophagy, remodelling of ECM and blood 
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vessels, inactivation of anti-proteinases, premature senescence and elevated 
mucous secretion and therefore is pivotal in COPD pathology (62). Both 
environmental or inflammatory cell derived ROS can influence inflammatory 
responses through activation and phosphorylation of the NFκB and the MAPK 
family, including ERK, JNK and p38 MAPK as well as PI3K (5, 63). 
 
Both oxidative and nitrative stress can activate macrophages and macrophages 
from smokers produce more H2O2 than those from non smokers. Equally, smokers 
and COPD patients have higher H2O2 levels in enhaled breath condensates than 
control patients, which is even higher during COPD exacerbations (64, 65). H2O2 
concentration in exhaled air is a marker of oxidative stress and can be used to 
monitor COPD exacerbations with it increasing with disease and decreasing with 
treatment (66) 
 
There are two main classes of antioxidant systems employed by the respiratory 
tract to counteract oxidative stress; non enzymatic and enzymatic antioxidants. Non 
enzymatic antioxidants include small molecules such as vitamin C, vitamin E, β-
carotene and thiol-containing compounds such as glutathione and thioredoxin. 
Enzymatic antioxidants include; glutathione peroxidise, superoxide dismutase, 
catalase, phase II detoxifying enzymes such as NADP(H) quinine oxidoreductase 1 
(NQO1) which contribute to xenobiotic detoxification and stress response proteins 
such as haem-oxygenase-1 (HO-1) (64, 65). Phase II detoxifying enzymes contribute to 
recycling of thiols or facilitate excretion of reactive metabolites during xenobiotic 
detoxification (67). Stress response proteins such as HO-1 and ferritin heavy and light 
chains are cytoprotective against various oxidant or pro-oxidant insults (67). HO-1 
contributes to the degradation of pro-oxidant haem molecule which also generates 
antioxidant products carbon monoxide and billirubin with release of iron (67). 
Ferritin is inducible by iron and is antioxidant by sequestering iron from 
participation in free radical formation (67). 
 
Most of the antioxidants and phase II cytoprotective genes are regulated by Nuclear 
factor erythroid 2 p45-related factor 2 (Nrf2) (5, 35). Nrf2 is a basic-leucine zipper 
transcription factor which plays a pivotal role in cellular defence against oxidative 
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stress (5) and is mainly expressed in alveolar macrophages and epithelial cells within 
the lungs (65). In response to various cellular stressors, Nrf2 detaches from its 
cytosolic inhibitor kelch-like ECH-associated protein 1 (Keap1), and translocates into 
the nucleus binding with cofactors to the anti-oxidant response element (ARE) of 
genes leading to the induction of stress response genes (5) including glutathione S-
transferases, NQO1 and HO-1 (65). 
 
Deletion of Nrf2 in airway epithelium has been shown to exacerbate acute lung 
injury and impairs inflammation resolution (68). Nrf2 also plays a role in protection 
against elastase induced emphysema and pulmonary inflammation (69). Impaired 
Nrf2 signalling causes decline in proteasomal activity and increases endoplasmic 
reticulum stress response in lungs of COPD patients (70). In one study, Nrf-2 deficient 
mice exposed for 6 months to cigarette smoke developed airway destruction (35, 71, 
72). Levels of Nrf2 are decreased in lungs of patients with COPD and this results in 
enhanced susceptibility to cigarette smoke induced damaged and more 
pronounced oxidative stress in the lung (5). However, in lung cancer uncontrolled 
Nrf2 activation provides a growth advantage and leads to chemoresistance of 
neoplastic cells (67). 
 
Overall data indicates that Nrf2 exerts its protective effects on COPD phenotypes 
through transcriptional activation of anti-proteases as well as antioxidants in 
alveolar macrophages (67).  
 
1.1.6.7 Epigenetics 
Epigenetic changes are also important in COPD. DNA is wrapped around histones 
and these histones can undergo post translational modifications, most commonly 
via acetylation. Histone acetyl transferases catalyse the addition of acetyl groups to 
specific lysine residues on the tails of histones 3 and 4. The positive charge of the 
acetyl groups reduces the affinity of the DNA to the histones allowing the 
transcriptional machinery to access the DNA enabling transcriptional activation. 
Histone deacetylase (HDACs) catalyse the opposite reaction therefore promoting 
transcriptional repression. Cigarette smoke inhibits HDACs enabling transcriptional 
activation of inflammatory genes such as TNFα and IL-8. HDAC2 expression has 
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been found to be decreased in lung macrophages from patients with COPD (1). 
Histone 4 acetylation at the NFκB binding site of IL-8 was increased in lung tissue 
from patients with COPD (73) suggesting that epigenetic changes could be 
contributing to the increases in cytokine expression in COPD. They showed a 
positive correlation between HDAC activity and disease severity, and the clinical 
stage of COPD could be related to reduced HDAC activity therefore increased 
transcription of inflammatory genes (73). 
 
1.1.7 Current Therapies  
Managing COPD is often complex due to its many systemic effects and co-
morbidities. Treatment aims to manage symptoms and reduce the frequency of 
exacerbations which worsen the disease and often result in hospital admission, 
presenting a huge cost for healthcare providers. Smoking cessation is the only 
therapeutic intervention shown to reduce disease progression (74). Pharmacological 
treatments include inhaled corticosteroids, bronchodilators and long term oxygen 
therapy and non pharmacological interventions include nutrition, exercise and lung 
volume reduction surgery (75).  
 
Bronchodilators are important for the treatment of COPD symptoms and are 
usually the initial choice of treatment (76). They have been shown to increase the 
FEV1 in patients (75) and to reduce airway inflammation in vitro (74). 
 
With inflammation being one of the major processes in COPD, many anti-
inflammatory therapies have clinical benefit in controlling the disease symptoms, 
progression, and preventing exacerbations. Inhaled corticosteroids are extensively 
used as anti-inflammatory treatment alone or in combination with long-acting 
bronchodilator drugs (76). Corticosteroids were a controversial treatment due to side 
effects and steroid resistance (77), although are now a more accepted treatment 
shown to reduce the frequency of exacerbations in COPD and hospital admissions, 
which therefore helps to slow the progression of the disease (75).  
 
Long term oxygen therapy is the only treatment so far shown to improve decline in 
lung function associated with COPD (75), although patient compliance is a problem.  
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COPD exacerbations are usually treated with a short course of oral corticosteroids 
or antibiotics (76). Antibiotics are used for their anti-infective properties however; 
there is evidence to suggest they have little effect on airway and systemic 
inflammatory markers so other treatment is required to manage symptoms and 
inflammation (76). Further studies are required to assess the effects of long-term 
antibiotics on exacerbation frequency with special attention to antibiotic resistance 
(76) and new safer anti-inflammatory agents need to be developed for treatment of 
acute exacerbations (76). A recent study has highlighted the heterogeneity of COPD 
exacerbations and defined independent subtypes of exacerbation with specific 
biomarkers, giving the potential for a more targeted and phenotype-specific 
management of COPD exacerbations in the future (78). 
 
1.1.8 Future therapies 
New anti-inflammatory therapies aim to target specific inflammatory mediators. 
Phosphodiesterase 4 (PDE4) is expressed by neutrophils, CD8+ cells and 
macrophages and its inhibition suppresses inflammatory cell function (75). However, 
inhibitors are associated with gastrointestinal side effects. There are a number of 
PDE4 inhibitors in clinical development for COPD reviewed in (43). LTB4 is also a 
target for inhibition and antagonists are in early stage clinical trials however, the 
efficacy of such drugs is as yet unknown (75).  
 
Other potential therapeutics for COPD is the molecular targeting of specific 
inflammatory signalling pathways. p38 MAPK activity is increased in alveolar 
macrophages from patients with COPD. Selective inhibitors of p38 MAPK have been 
shown in vitro to inhibit IL-8 production and increase the suppressive effect of 
dexamethasone (79). A study in COPD patients demonstrated p38 MAPK inhibitor SB-
681323 decreased LPS stimulated TNFα in serum, and sputum neutrophils. 
However, there are multiple side effects reported (25, 74) and so p38 MAPK inhibitors 
that can be administered by inhalation are now being explored (37, 43, 74). 
 
PI3K activity is significantly increased in peripheral blood monocytes from patients 
with COPD compared with control subjects and is associated with a decreased 
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sensitivity to corticosteroids (79). Addition of a PI3K inhibitor restores sensitivity and 
a number of these inhibitors are under development which may be effective in 
steroid insensitive COPD (43, 79). 
 
The NFκB pathway is a key target for anti-inflammatories and targeting this 
pathway for COPD treatment has been reviewed extensively (77). Numerous IKK2 
inhibitors are being evaluated as potential anti-inflammatories however, as yet 
there have been no clinical trials and animal data suggests that inhibition of this 
pathway may have multiple side effects (37, 74). HDACs also play a role in the 
transcriptional regulation of NFκB and represent another therapeutic target (1). 
 
Levels of TNFα in induced sputum correlate directly with pack-years of smoking and 
inversely with FEV1. Etanercept, infliximab and adalimumab antibodies have been 
developed clinically to inhibit TNFα in inflammatory diseases. Infliximab has been 
found to have little effect on inflammatory mediators or spirometry measurements 
in COPD patients. In addition, side effects of TNFα  blockage include increased risk 
of infection (37, 74). Further studies are required to determine if TNFα antagonists are 
beneficial to all COPD patients or specific phenotypes of COPD patients (43). Many 
other different inflammatory mediators have been targeted as potential therapies 
reviewed in (80). 
 
Proteases are also a therapeutic target. Inhibitors of neutrophil elastase have been 
studied now for many years but compounds failed in clinical development because 
of poor pharmacokinetics and low therapeutic index (43) although this area is still 
being pursued. Equally α1 antitrypsin replacement therapy in patients with α1 
antitrypsin deficiency related emphysema has not yet been proven effective (43). 
MMP inhibitors are of interest in COPD therapy however, these inhibitors tend to 
have adverse side effects and further development is required for highly selective, 
oral MMP inhibitors with acceptable pharmacokinetics (81). 
 
Many of the pathogenic mechanisms in COPD involve oxidative stress and hence 
this is a target for treatment by decreasing oxidant generation or enhancing 
antioxidants. Antioxidant therapy for COPD has been extensively reviewed recently 
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(5, 62). Current agents are used symptomatically, mainly for mucolytic activity. 
However, other antioxidant therapies may be of therapeutic benefit either alone or 
in combination with other therapeutic agents and this requires further investigation 
with carefully designed clinical trials defining COPD phenotypes (62). 
 
Resistance to glucocorticoids is a common problem in the treatment of COPD and 
therefore restoring steroid sensitivity is a potential target in COPD (79). 
Glucocorticoid suppression of inflammation requires recruitment of HDAC2 
resulting in deacetylation of histones and decrease in inflammatory gene 
expression (43). Oxidative stress reduces nuclear HDAC2 expression thereby 
contributing to the amplification of disease severity and corticosteroid resistance 
(65). Activation of Nrf2 has been shown to reverse corticosteroid insensitivity in 
alveolar macrophages from COPD patients by dinitrosylating HDAC2 (82). Nrf2 is also 
a novel therapeutic target in COPD with its ability to mitigate inflammation, 
improve antibacterial defence and restore corticosteroid responses (83). 
 
Many of these therapies are too toxic to be used systemically and therefore inhaled 
preparations are being investigated to reduce lung inflammation with low systemic 
exposure (84). However, systemic inflammation is also important in COPD pathology 
and its co-morbidities and requires treatment but inhaled preparations may have 
less effect on systemic inflammation (84). Investigation is required to look at if 
successful treatment of co-morbidities positively influences the course of the lung 
disease (84). 
 
All of these treatments only seem to target one aspect of COPD either specific 
molecules, symptoms or exacerbations even though COPD is a multifactorial 
disease. New therapies are required that are beneficial in many different aspects of 
the disease without having multiple side effects which outweigh their benefits. 
Vitamin D has this potential.  
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1.2 Vitamin D 
Vitamin D is a steroid hormone thought to have first been produced over 200 
million years ago in phytoplankton exposed to sunlight (85).  Conventionally vitamin 
D is known for its actions in bone mineralisation and calcium homeostasis although 
the role of vitamin D is a field which is expanding rapidly with deficiencies of 
vitamin D being a worldwide problem. Vitamin D deficiency is defined as being 
below 30 ng/ml of serum 25(OH)D (25-hydroxyvitamin D) the inactive form of the 
vitamin (86). Deficiencies of vitamin D in children are associated with growth 
retardation and symptoms of rickets. In adults it can exacerbate osteoporosis 
increasing the risk of fractures (85). There is now mounting evidence supporting the 
action of vitamin D in immunity and inflammation with deficiencies now also being 
associated with an increased risk of some cancers, autoimmune and infectious 
diseases (85).  The discovery of the vitamin D receptor expressed in many different 
cell types and organs around the body ignited further interest in this hormone (87). 
Over the last 5-10 years there has been an exponential increase in the research on 
vitamin D for many diseases including different cancers, multiple sclerosis, diabetes, 
tuberculosis, asthma and heart disease (Figure 1.3). 
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1.2.1 Sources and Metabolism  
1, 25 dihydroxyvitamin D3 (1,25(OH)2D3) is the active form of vitamin D, which is 
mainly sourced from endogenous production within the skin but is also found in 
some dietary products. In the skin, UVB radiation on 7-dehydrocholesterol leads to 
the production of vitamin D metabolites (88). Melanin impairs the ability of the solar 
radiation to produce vitamin D within the skin of those of Afro-Caribbean ethnicity 
so they have much lower circulating levels of 25 hydroxyvitamin D (25(OH)D) than 
those of white ethnicity (89). Dietary sources of vitamin D metabolites include 
fortified dairy products, fatty fish and fish liver oils (88).  
The precursors of vitamin D from the skin and the gut are hydroxylated in the liver 
to form 25(OH)D through the action of mitochondrial cytochrome p450 enzymes 
CYP3A4 and CYP2R1 (90). The active form of vitamin D is formed by further 
hydroxylation of 25(OH)D3 to 1,25(OH)2D3  catalysed by 25-hydroxyvitamin D3 1-
alpha hydroxylase (CYP27B1) usually within the kidneys. The main regulatory 
pathway modulating the expression of this enzyme is the parathyroid hormone 
which upregulates 1 alpha hydroxylase in calcium and vitamin D deficiency. More 
recently many different cell types have been shown to express CYP27B producing 
high local concentrations of vitamin D providing a role in autocrine and paracrine 
signalling (91, 92).   
 
25(OH)D is the major circulating form of vitamin D and levels of this form are of 
clinical use being indicative of an individual’s vitamin D status with  serum 
concentrations of 30-50 ng/ml considered as sufficient (92, 93) . Vitamin D circulates 
bound to vitamin D binding protein (DBP) also known as group-specific component 
(Gc) which is an α2 macroglobulin belonging to the serum albumin superfamily. The 
major function of DBP is the binding, transport and solubilisation of vitamin D and 
its metabolites (94), however it is a multifunctional protein also involved in 
macrophage activation and bone resorption. Large amounts of vitamin D in the 
circulation can saturate the vitamin D binding proteins leading to vitamin D toxicity 
and hypercalcemia with renal failure and hypertension due to the build up of 
calcium phosphate crystals in the kidney and vasculature.  
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Being lipophillic, 1,25(OH)2D3  is able to traverse the cell membrane and acts within 
the cell by binding to the nuclear vitamin D receptor (VDR). VDR’s are ligand 
activated transcription factors that interact with vitamin D response elements 
(VDREs) on vitamin D regulated genes either as homodimers or as heterodimers 
with the retinoid x receptor (95). Vitamin D regulates over 200 genes, these include 
genes for cellular proliferation, differentiation and apoptosis (96). Another 
modulator of vitamin D is the mitochondrial cytochrome P450 24-hydroxylase 
(CYP24A1) which inactivates calcitriol into water soluble derivatives (91). Vitamin D 
binding to the VDR enhances CYP24A1 and downregulates CYP27B1 which is an 
important negative feedback mechanism regulating vitamin D levels (91, 92). 
 
It has been shown that the VDR can elicit both genomic and rapid responses of 
vitamin D (97) however there has also been speculation of a different membrane 
receptor for this ligand (90). The 1,25-membrane associated rapid response to 
steroids binding (MARRS) is a newly described receptor isolated from chick 
intestinal basolateral membranes (98). It has since been shown to be present in 
mammalian cells and demonstrates rapid responses to vitamin D (98). It is identical 
to ERp57, GRp58, PDIA3 (endoplasmic reticulum protein of 57 kDa, glucose 
regulated protein of 58 kDa and Protein disulfide isomerise associated 3 
respectively) (98). It is a glycoprotein specific thiol oxidoreductase important in the 
endoplasmic reticulum for quality control of newly synthesised glycoproteins but 
has been most widely studied for its role in the immune system in the assembly of 
the heavy chain of the major histocompatibility complex (MHC) class I molecules 
(99). 
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1.2.2  Immunomodulation 
The discovery of the expression of the VDR and hydroxylase enzymes by immune 
cells led to a surge of research into the area. It is now apparent that circulating 
1,25(OH)2D3  is not the likely source of vitamin D activity as levels are only around 
0.1 nmol/L whereas in vitro studies suggest levels of 1-100 nmol/L are required for 
its modulatory activity (100). It is likely that high levels of circulating 25(OH)D are 
converted locally within the cellular microenvironment by the expression of CYP 
enzymes found in the mitochondria of  macrophages and dendritic cells (101).  
Upregulation of CYP27B1 and the VDR enables the activated macrophage to use 
25(OH)D as a substrate for production of the active form after internalisation of the 
vitamin D binding protein (DBP) attached to 25(OH)D from the extracellular fluid.  
VDR is constitutively expressed on APC’s and dendritic cells suggesting a role in 
antigen presentation (86), and also by macrophages and activated lymphocytes (88). 
Antigen-presenting cells, essential for the initiation and maintenance of cell-
mediated immune responses, can be inhibited directly by vitamin D. The expression 
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of MHC class II and co-stimulatory receptors is inhibited, as is the maturation of 
dendritic cells (102). The inflammatory stimuli interferon gamma (IFN-ɣ) and LPS have 
been shown to upregulate hydroxylase expression in macrophages (92). Vitamin D 
degrading enzyme is also expressed by monocytes and macrophages inducible by 
vitamin D providing a negative feedback loop (88). 
 
A well studied area of vitamin D is its effects on T cell responses where it targets 
transcription of T helper 1 (Th1) cytokines such as IL-2, granulocyte macrophage 
colony stimulating factor (GM-CSF) and IFN thereby shifting the response from Th1 
to Th2 inducing immune tolerance. IL-12 the main controller of Th1 vs Th2 
response, is inhibited by vitamin D and this therefore leads to an inhibition of Th1 
and activation of Th2 (88). Supporting this vitamin D induces the expression of Th2 
cytokines IL-4, 5 and 10 (88). Conversely, vitamin D insufficiency deregulates the 
balance between type 1 and 2 immunity leading to over expression of Th1 
cytokines. By blocking these it prevents further antigen presentation and 
recruitment of T lymphocytes. Vitamin D has potent antiproliferative effects on T 
cells, principally that of the Th subgroup, and suppresses B cell antibody production 
both directly and indirectly in vitro (86, 100).  
 
Perhaps one of the most important modulatory actions of 1,25(OH)2D3 is its effect 
on regulatory T cells (Tregs) which prevent the activation of peripheral autoreactive 
T cells. In the absence of 1,25(OH)2D3 the numbers and functions of Tregs are 
reduced, potentially contributing to the development of autoimmune diseases, 
such as multiple sclerosis and type 1 diabetes, where low vitamin D status is 
associated with an increased risk of developing these disorders (103, 104). The role of 
vitamin D in autoimmune diseases has been reviewed recently (105). 
 
Vitamin D also modulates the expression of a wide range of cytokines including IL-
1β, IL-6, IL-8, IL-10, IL-12 and TNFα (106-108). 
 
There is an expanse of literature on vitamin D modulating the key inflammatory 
transcription factor NFκB, with vitamin D inhibiting NFκB activity (36, 108, 109), 
increasing IκBα expression (110), increasing IκBα mRNA stability and decreasing IκBα 
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phosphorylation (111). Vitamin D also activates NFκB activity increasing IKK (112, 113). 
So vitamin D has been shown to both inhibit and activate NFκB activity which is 
important in different cell types for it to modulate immune responses aiding the 
clearance of pathogens by increasing the expression of anti-microbial peptides, but 
limiting local tissue damage by decreasing pro-inflammatory cytokine production 
(114). NFκB has been shown to inhibit VDR function and integrate into the VDR 
transcriptional complex (115). On a transcriptional level, NFκB downregulates 1α 
hydroxylase activity during chronic inflammation (90), suggesting that it acts to 
prevent vitamin D activation locally so that it is unable to act in an 
immunomodulatory capacity. 
 
Other pathways modulated by vitamin D include p38 MAPK (116), PI3K (117), JNK (118), 
ERK (119), Rho kinase (120-122). 
 
 
1.3 Vitamin D in lung infection and disease 
In addition to immune cells, respiratory epithelial cells can also constitutively 
convert inactive 25(OH)D to 1,25(OH)2D3, enabling high local concentrations of 
active vitamin D to increase the expression of vitamin D-regulated genes in the lung 
with important innate immune functions (123). Black et al (2005) found a dose 
responsive relationship between serum concentrations of 25(OH)D and FEV1. 
Vitamin D deficiency has also been shown to increase the risk of upper respiratory 
tract infections, tuberculosis and to decrease the FEV1 in asthma and respiratory 
diseases (85).  Low serum levels of 25(OH)D in lung transplant recipients have been 
associated with increased incidence of acute rejection and infection. (124) 
 
A large cross-sectional study has shown that vitamin D intakes and higher serum 
levels are associated with improved lung function in adults (125) and similar findings 
have been reported in adolescents (126). Many recent literature reviews have 
highlighted the potential of vitamin D in lung diseases including asthma, cystic 
fibrosis, tuberculosis and respiratory tract infections which have led the way to 
investigations into lung cancer and COPD (127). 
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1.3.1 Tuberculosis 
Exposure to sunlight has been known for more than 100 years to help with the 
treatment of tuberculosis (85), although the first indicator of vitamin D having anti-
microbial activity against Mycobacterium tuberculosis was from studies in the 
1980s, where adding vitamin D to monocytes and macrophages infected with M. 
tuberculosis showed that the bacterial load was reduced (128). More than 60 years 
ago clinical studies were carried out administering oral vitamin D as a treatment for 
mycobacterial infections with high success rates (129). A recent meta-analysis found 
that low serum 25(OH)D levels are associated with higher risk of active tuberculosis 
(130), and several studies have associated low serum 25(OH)D levels with increased 
susceptibility to tuberculosis and disease progression (128). 
Tuberculosis patients administered vitamin D or placebo following the sixth week of 
standard tuberculosis treatment had higher sputum conversion and radiological 
improvement (100%) compared to a placebo group (76·7%) (131). Addition of 
1,25(OH)2D3  to primary human macrophages infected with virulent M. tuberculosis 
reduced the number of viable bacilli (132). Adding a single oral dose (2·5 mg) of 
vitamin D to the treatment regimen of patients with tuberculosis enhanced 
significantly the ability of the participants’ whole blood to restrict growth of 
mycobacteria in vitro without affecting antigen-stimulated IFN-ɣ responses (133). A 
recent randomised controlled trial of adjunctive vitamin D in adults with sputum 
smear-positive pulmonary tuberculosis showed that vitamin D significantly 
hastened sputum culture conversion but only in a specific subset of the study 
population with the tt genotype of Taq1 VDR polymorphism (134). 
 
The immune system is able to detect invading pathogens such as M. tuberculosis via 
pathogen-associated molecular patterns (PAMPs); structural proteins expressed by 
the pathogen which are detected by Toll-like receptors (TLRs) in the host. PAMPs 
shed from M. tuberculosis interact with the TLR2/1 dimer on macrophages, 
resulting in the up-regulation of both CYP27B1 and VDR (96, 135). It has been shown 
recently that IL-15 is responsible for the induction of CYP27B1, leading to 
bioconversion of 25(OH)D to 1,25(OH)2D3 , VDR activation and induction of 
cathelicidin (136). The cathelicidin gene encodes an anti-microbial peptide, LL-37, and 
this gene, in humans (but not in mice), contains a vitamin D response element. 
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Therefore binding of vitamin D leads to LL-37-mediated killing of M. tuberculosis 
(129). The cathelicidin gene is expressed in respiratory epithelial cells (123) and vitamin 
D induction of cathelicidin has been shown in a number of cell lines including 
bronchial epithelial cells (137). 1,25(OH)2D3  modulates the balance in cytokine 
production towards an anti-inflammatory profile by repression of TLR2, TLR4 and by 
increasing cathelicidin (138). 1,25(OH)2D3 modulates M. tuberculosis induced 
cytokines in peripheral blood mononuclear cells (PBMC) by dose dependently 
suppressing IL12p40 and IFNɣ (139). It also attenuates M. tuberculosis induced MMP-
7 and MMP-10 expression, and inhibited MMP-9 expression, secretion and activity 
irrespective of infection in PBMC (140). In addition, 1,25(OH)2D3  increases TIMP1 
expression in PBMC from patients with tuberculosis compared to healthy controls 
(141). 
 
1.3.2 Influenza and the common cold 
Influenza A virus causes severe epidemics of respiratory illness in humans and is 
transmitted through airborne droplets and by direct contact. It is characterized by 
acute neutrophil infiltration and narrowing of the bronchioles (142). Controversy 
remains concerning whether there is a direct link between the seasonality of 
influenza and vitamin D deficiency, which is also observed more commonly in 
winter (89). Influenza infection involves both innate and adaptive arms of the 
immune system. Although vitamin D can inhibit pro-inflammatory cytokine release 
by macrophages, its ability to up-regulate the expression of anti-microbial peptides 
is relevant, as these peptides can also exhibit anti-viral activity. In addition, viral 
infection increases activation of vitamin D and increases cathelicidin production 
further (123). Not only do immune cells secrete these anti-microbial peptides, but 
epithelial cells present in the upper and lower airways can also secrete them as a 
host defence mechanism against infection (89). Upper respiratory tract infections 
(URTI), or ‘common colds’, are the most widespread of infectious diseases, with 
more than 200 viruses contributing to the clinical symptoms. Early epidemiological 
studies found a strong association between rickets and RTI (143), and a recent large 
cross-sectional study of the US population reported that vitamin D status is 
associated inversely with recent URTI and that the association may be stronger in 
those with respiratory diseases, such as asthma (144). A recent study of young 
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Finnish men serving on a military base observed an association between low 
vitamin D status and days of absence from duty due to physician-diagnosed acute 
respiratory tract infections (93). In addition, a recent double blind randomised 
control trial evaluated vitamin D supplementation on the incidence of seasonal 
influenza A in schoolchildren. Children supplemented with vitamin D had a 
reduction in influenza A incidence and this was more prominent in those who had 
not taking other vitamin D supplements. This suggests vitamin D supplementation 
of children during winter may reduce the incidence of this infection (145). Further 
randomized controlled trials are needed to examine the direct effect of vitamin D 
supplementation and to establish the optimal serum levels of 25(OH)D to aid 
prevention of RTI. 
 
1.3.3 Cystic fibrosis 
Cystic fibrosis is a hereditary disease which not only causes mucous hypersecretion 
within the lungs and resulting airway obstruction and inflammation, but also affects 
other systems including pancreatic secretions. Due to the increase in mucous, 
patients are prone to frequent infections and reduced pancreatic secretions result 
in patients having problems with malabsorption of fat-soluble vitamins such as 
vitamin D. Several studies have shown that patients with cystic fibrosis have 
reduced circulating levels of 25(OH)D despite supplementation (146), suggesting that 
either higher than normal levels of supplementation are needed to increase serum 
concentrations or that there is insufficient conversion of the dietary vitamin D to 
25(OH)D. It has been reported recently that portable tanning devices can improve 
the vitamin D status of patients with cystic fibrosis (CF) during the winter months 
(147) but caution is required to avoid overexposure to UVB radiation. DBP has also 
been associated with cystic fibrosis with a healthy level in the circulation defined as 
300–600 mg/l, and low concentrations have been reported in acute respiratory 
distress syndrome and in the sera of patients with CF (94, 148). There is also a higher 
proportion of low bone density and osteoporosis within this population group. In 
the previously mentioned study showing that cathelicidin can be induced by vitamin 
D in primary bronchial epithelial cells, cells from patients with CF also showed 
increased cathelicidin expression (149), suggesting that vitamin D can augment anti-
bacterial activity in airway epithelia in cystic fibrosis.  
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A recent cellular study using cells from patients with cystic fibrosis showed that 
treatment with vitamin D prior to exposure to P. aeruginosa LPS and conditioned 
media  produced lower levels of IL-6 and IL-8 expression with a decrease in IκBα 
phosphorylation, increased total IκBα and increase in cathelicidin mRNA and 
protein (150). This may provide a novel therapy for prevention and treatment of 
airway infections in this disorder. 
 
1.3.4 Asthma 
Asthma and atopic diseases are characterized by inflammatory responses initiated 
and sustained by inappropriate Th lymphocyte responses of the Th2 phenotype. 
Direct evidence for a role of vitamin D in asthma comes from studies showing that 
VDR variants are a risk factor for asthma (151). An inverse association between 
maternal intakes of vitamin D during pregnancy and early childhood wheezing has 
been reported in studies from the United States (152) and the United Kingdom (153). 
As stated above, vitamin D is associated with skewing the immune response to a 
Th2 phenotype, leaving the possibility that vitamin D may potentiate Th2 responses 
in adult asthmatic patients and clinical trials are required to address this concern. 
On the other hand, the potential for vitamin D to increase pulmonary defence 
against respiratory infections may, in the same way as in COPD, reduce the 
triggering of asthma exacerbations caused by RTI (154). This is supported by the 
previously mentioned particularly strong negative association between vitamin D 
status and URTI in individuals with asthma in the Third National Health and 
Nutrition Examination Survey (NHANES III) study (144). 
 
Glucocorticoids are the most effective anti-inflammatory treatments available for 
many immune diseases, including asthma. However, glucocorticoid resistance or 
insensitivity in some patients with asthma represents an important barrier to 
effective treatment and accounts for significant health-care costs (155). Recently, 
some evidence has emerged that administration of vitamin D to glucocorticoid-
resistant asthmatic patients can enhance subsequent responsiveness to 
dexamethasone by restoring the defective IL-10 response to glucocorticoids by 
CD4+ T cells in these individuals (156). This finding provides encouragement to 
 50 
undertake trials of vitamin D in overcoming glucocorticoid resistance in both 
asthma and a number of other inflammatory diseases (155).  
 
In addition, in asthma there is a degree of airway remodelling characterised by the 
metaplasia of mucous glands, basement membrane thickening, increased ECM 
deposition, subepithelial fibrosis and smooth muscle hypertrophy/hyperplasia (157, 
158). ‘A disintegrin and metalloproteinase-33’ (ADAM33) has been identified as a 
novel asthma susceptibility gene by genome-wide screening, and is now known to 
play an important role in airway remodelling. Its level of expression is associated 
with asthma development and severity and it declines with therapeutic 
interventions (151). In vitro studies have shown that 1,25(OH)2D3 has a direct anti-
proliferative effect on human airway smooth muscle cells and can inhibit the 
expression of ADAM33 (151), suggesting a further beneficial role for vitamin D in the 
prevention and treatment of asthma. 
 
1.3.5 Lung cancer 
Lung cancer is the leading cause of mortality from cancer worldwide (WHO), and is 
responsible for over twice the number of deaths than any other cancer. It has a 
poor prognosis, with only a 10% survival rate at 5 years (159). COPD is the single most 
important risk factor for the development of lung cancer after smoking exposure 
(160). Lung cancer is thought to be driven by DNA damage caused by excessive 
inflammation and lack of repair processes within the lung, resulting in genomic 
instability (160-162). Around 50-70% of patients with lung cancer suffer from COPD: 
however, a causal relationship between the two has not yet been established (163).  
 
The effects of vitamin D in lung cancer have been reviewed extensively (164). 
1,25(OH)2D3 and analogues significantly inhibit cell proliferation in a number of lung 
cancer cell lines (165-167). In addition, 1,25(OH)2D3 has also been shown to reduce 
tumour volume,  metastasis and angiogenesis in different animal models of lung 
cancer (168-173).  
 
In the UK there is a significant gradient in UVB exposure from north to south and a 
better lung cancer survival rate in patients with higher exposure (174, 175). However, 
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there is no clear finding from association studies with increased circulating 25(OH)D 
associated with improved survival in lung cancer patients (176) and no association 
between 25(OH)D status and total or lung cancer mortality in 16,818 subjects from 
the third National Health and Nutrition Examination Survey (177).  
 
Vitamin D has many antitumorigenic properties, and some types of lung cancer 
have developed resistance to vitamin D by modulating expression of CYP27B1, 
CYP24A1 and the VDR. In contrast to normal airway epithelial cells, some lung 
cancer cell lines have been shown to express very low CYP27B1 or not at all (123, 178). 
Several studies have demonstrated that CYP24A1 is overexpressed and VDR 
reduced in lung tumor tissue compared with normal tissue (179, 180). Also higher VDR 
expression has been shown to correlate with longer survival in lung 
adenocarcinoma (181). Serum DBP levels are a significant independent factor 
associated with better cancer outcome in operated lung cancer patients (182). 
 
1.3.6 COPD 
In comparison to research in other lung diseases, vitamin D in COPD is under-
researched. Most of the studies on vitamin D and COPD are suggestive with vitamin 
D found to modulate mediators important in COPD pathology in other disease 
types. 
A randomised single centre double blind placebo controlled trial of 182 patients 
with moderate to very severe COPD giving high dose vitamin D looked at the time 
to first exacerbation as a primary outcome. There was no reduction in incidence of 
exacerbations on vitamin D treatment, although a small subset of participants with 
severe vitamin D deficiency at baseline had a significant reduction in exacerbations. 
This does suggest that monitoring vitamin D deficiency in this population is very 
important and also that perhaps patients with severe COPD taking maximum 
tolerated doses of other medication are no longer responsive to vitamin D 
treatment and that vitamin D supplementation needs to be commenced earlier in 
the disease (183). Lower serum levels of 25(OH)D concentrations are significantly 
associated with an increased risk of COPD (184)                                                                                                                                                                                                                                                                                                                                              
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DBP is a highly polymorphic gene and it has been demonstrated that 
polymorphisms in DBP are significantly correlated with susceptibility and severity of 
COPD (94). DBP has also been reported to be involved in the chemotactic response of 
complement attracting neutrophils to the site of inflammation, an important step in 
the pathology of COPD (94).  
 
Vitamin D plays a role in influencing skeletal muscle function, with deficiency 
resulting in muscle weakness, and VDRs are present in this tissue (185). 
Polymorphisms in the VDR can influence muscle weakness (186), therefore vitamin D 
may not only be beneficial in the respiratory pathology but also the systemic 
symptoms of COPD.  
 
Franco et al (2009) found that 51% of the COPD patients that they tested had 
osteoporosis and a low vitamin D status, and that the prevalence of osteoporosis 
was correlated with the severity of COPD (187). This suggests that vitamin D may be 
beneficial in patients with COPD and so the future may involve vitamin D 
supplementation in order to test this (188). In one study the prevalence of 
osteoporosis in COPD patients increased over a 3 year period and risk factors for 
the development of osteoporosis included vitamin D deficiency (189). 
 
On a cellular and molecular level, 1,25(OH)2D3  has a number of effects that may be 
relevant to COPD such as inhibiting the formation of MMP’s as well as influencing 
collagen synthesis suggesting it could influence tissue remodelling and alveolar 
destruction. Song et al (2007) have shown that 1,25(OH)2D3 has a direct 
antiproliferative effect on human airway smooth muscle cells and an inhibitory 
effect on MMP-9 mRNA and protein levels suggesting a role in preventing airway 
remodelling (190).  Vitamin D modulates airway smooth muscle function in COPD 
which has been reviewed (191). 
 
Vitamin D also induces the expression of the anti-microbial peptide cathelicidin in 
both alveolar macrophages and airway epithelial cells which may be important in 
the innate response to infection in exacerbations of COPD (137, 149). Recent research 
has shown that respiratory epithelial cells constitutively  activate vitamin D enabling 
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high local concentrations of active vitamin D to develop suggesting that vitamin D is 
required by these cells for certain functions (123). As in asthma, steroid resistance is 
also prominent in COPD and therefore the potential of vitamin D to restore steroid 
sensitivity would also be beneficial (192). 
 
As vitamin D has been shown to have numerous immunomodulatory actions which 
may make it beneficial in the inflammation of COPD, and respiratory epithelial cells 
have been shown to constitutively activate vitamin D and are an important source 
of inflammatory mediators and proteases involved in the pathology of COPD, 
vitamin D may be able to beneficially modulate inflammation, protease destruction 
and oxidative stress in airway epithelial cells from patients with COPD. 
 
There is therefore broader potential for vitamin D in prevention and treatment of 
this disease. 
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1.4 Aims 
The hypothesis is that vitamin D will beneficially modulate the expression of 
inflammatory mediators and also oxidative stress, both important in COPD 
pathology, in human airway epithelial cells. 
 
Therefore the aims of this study were: 
 To characterise the expression of inflammatory mediators important in 
COPD pathology in human airway epithelial cells and find a suitable model 
cell line of primary small airway epithelial cells. 
 To investigate the effects of vitamin D on the expression of inflammatory 
mediators important in COPD pathology in primary airway epithelial cells 
and lung epithelial cell lines both basally and in response to inflammatory 
stimuli. 
 To examine the effects of vitamin D on oxidative stress in primary airway 
epithelial cells and cells lines. 
 To determine the mechanism of action of vitamin D in airway epithelial cells. 
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Chapter 2:  
Material and Methods 
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2.1 Materials 
2.1.1 General Materials 
 Recombinant Human TNFα was purchased from R&D Systems (Abingdon, UK), LPS 
(E.coli 0111:B4), 1,25(OH)2D3, LY294002, SB203580, PD98059 and MG132  were 
purchased from Calbiochem (Merck Chemicals Ltd, Nottingham, UK). LPS 
(Pseudomonas aeruginosa serotype 10) and dimethyl sulfoxide (DMSO) were 
purchased from Sigma Aldrich (UK, Poole). Y27632 and SP600125 were purchased 
from Tocris Bioscience (Bristol, UK). 
All general laboratory agents and consumables were purchased from Thermo Fisher 
Scientific (Loughborough, UK) unless otherwise stated. 
 
2.1.2 Cell Culture  
2.1.2.1 Consumables 
T25 and T75 tissue culture flasks, cryovials and stripettes were purchased from 
NUNC. 0.45 µM filters and syringes were purchased from Sigma Aldrich, 15 and 50 
mL falcon tubes were purchased from BD Biosciences (Oxford, UK). Eppendorfs and 
pipette tips were purchased from Starlabs (Milton Keynes, UK). 
 
2.1.2.2 Cell Culture Reagents 
Foetal calf serum (FCS) was purchased from Biosera (East Sussex, UK). Trypan blue 
0.4% and bovine serum albumin (BSA) were purchased from Sigma Aldrich. RPMI 
1640 media, RPMI 1640 phenol red free media, MEM, 10,000 U/mL penicillin,  
10,000 μg/mL streptomycin, 200 mM L-glutamine, 0.25% trypsin-EDTA and LHC 
basal medium 1x liquid were purchased from Invitrogen (Paisley, UK). SAGM and 
SABM, HBSS and TE for primary cells were purchased from Lonza (Slough, UK). 
Vitrogen and human fibronectin were purchased from BD Biosciences.  
 
2.1.3 Nucleic acid isolation 
Tri-reagent solution was purchased from Applied Biosystems (Warrington, UK), 1-
bromo-3-chloro propane (BCP), absolute ethanol, and 2-propanol were purchased 
from Sigma Aldrich. 
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Cells to cDNA lysis buffer, DNase I and 10 x DNase I buffer were obtained from 
Applied Biosystems. RNase inhibitor was purchased from Promega (Southampton, 
UK). Mouse moloney murine leukaemia virus reverse transcriptase , 5 x forward 
strand buffer, 0.1 M DTT, and random primers were procured from Invitrogen and 
dNTP mix was purchased from Bioline (London, UK).  
 
2.1.4 qRT-PCR 
SYBR green jumpstart readymix was purchased from Sigma Aldrich, TaqMan reverse 
transcription reagents from Applied Biosystems, specific primer sequences were 
purchased from Invitrogen. Ready-made primers, 0.1 and 0.2 mL PCR tubes were 
purchased from Qiagen (Crawley, UK). 
 
2.1.5 Protein Detection  
2.1.5.1 Western Blotting 
NuPAGE LDS sample buffer (4x),  NuPAGE reducing agent (10x),  4-12% Bis-Tris gel, 
20 x transfer buffer, 20 x MOPS SDS running buffer and NuPAGE antioxidant were 
purchased from Invitrogen. Broad range molecular weight marker was purchased 
from BIO-RAD (Hertfordshire, UK). Supersignal west dura ECL was purchased from 
Thermofisher Scientific and RapidStep ECL reagent was from Merck Millipore 
(Nottingham, UK). 
Rabbit monoclonal anti-Nrf2 antibody was procured from Abcam (Cambridge, UK ). 
Goat anti-rabbit HRP antibody was purchased from Santa Cruz. Monoclonal anti-β-
actin antibody was purchased from Sigma Aldrich. Polyclonal goat anti-mouse HRP 
antibody was from Dako (Ely, UK). Re-blot Plus antibody stripping solution was 
purchased from Millipore. 
 
2.1.5.2 Flow cytometric bead array 
The flow cytometric bead array was purchased from BD Bioscience and contained:  
human IL-1β, IL-6, IL-8, IL-10, IL-12p70, and TNFα capture beads, human 
inflammatory cytokine PE detection reagent, human inflammatory cytokine 
standards, cytometer  setup beads, PE positive control detector, FITC positive 
control detector, wash buffer and assay diluent. 
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2.1.5.3 Gelatin Zymography 
Tris base, HCl, NaCl, CaCl2, Tween-20, SDS, ammonium persulfate, TEMED, 
methanol and glycine were purchased from Thermofisher Scientific. 30% 
acrylamide: 0.8% bis-acrylamide was purchased from BIO-RAD. Gelatin, Triton-
X100, bromophenol blue, glycerol, coomassie brilliant blue and acetic acid were 
obtained from Sigma Aldrich. MMP9 control was from R&D systems. 
 
2.1.6 Reactive oxygen species assay 
2, 7’-dichlorodihydrofluoresceindiacetate (H2DCFDA) was obtained from Invitrogen. 
96 well clear bottom black sided flurorescence plates were purchased from 
Thermofisher Scientific.  
 
2.1.7 Cytotoxicity/Proliferation Assay 
Cell Titer 96 AQueous One Solution Reagent was purchased from Promega. Tert-Butyl 
hydroperoxide (tBHP) and hydrogen peroxide (H2O2) were obtained from Sigma 
Aldrich. 
  
2.1.8 ELISA 
96 well flat bottom Immuno Maxisorp ELISA plate were from Thermofisher 
Scientific,  0.05% Tween 20 and H2SO4 was obtained from Sigma Aldrich. Primary 
mouse anti-MUC5AC clone 45M1 antibody was from Invitrogen. Secondary goat 
anti-mouse HRP antibody was purchased from Dako. 3, 3’, 5, 5’ – 
tetramethylbenzidine peroxide solution (TMB substrate) was obtained from BD 
Biosciences.  
 
2.1.9 Immunohistochemistry for MUC5AC expression 
Microscope slides and glass cover slips were from Thermofisher Scientific. Porcine 
gelatine, paraformaldehyde, Triton X-100 and 4’, 6-diamidino-2-phenylindole (DAPI) 
were from Sigma Aldrich. Mouse anti-human MUC5AC clone 45M1 antibody, goat 
anti-mouse alexofluor 488 nm antibody and goat serum were from Invitrogen. Goat 
IgG was purchased from Santa Cruz (Middlesex, UK). Fluoromount G was from 
Cambridge Biosciences (Cambridge, UK). 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Heat Inactivation of FCS 
FCS was defrosted in a 37°C water bath and then placed at 57°C for 30 minutes to 
heat inactive the serum before separating into 50 mL aliquots for storage at -20°C 
to avoid freeze-thaw cycles. 
 
2.2.1.2 Preparation of cell culture media 
All media supplements (and 0.25% Trypsin-EDTA) were defrosted in a 37°C water 
bath and then separated into 5 mL aliquots to store at -20°C. Before addition to 
media, all supplements including FCS were first filter sterilised using a 0.45 µM 
filter. 
 
2.2.1.3 Cells 
2.2.1.3.1 A549 
A549 were purchased from the European Collection of Cell Cultures (ECACC) 
(Salisbury, UK) and are a human alveolar carcinoma cell line derived from a 58-year-
old caucasian male (193) (ECACC). They are used as an example of an alveolar type II 
cell line and were originally developed to study surfactant synthesis and secretion 
(193). A549 were cultured in RPMI-1640 media containing 100 U/mL penicillin, 100 
µg/mL streptomycin, 2 mM L-glutamine, and 10% FCS.  At 80-90% confluency, cells 
were passaged by firstly washing with phosphate buffered saline solution (PBS) 
followed by addition of 5 mL 0.25% trypsin-EDTA 1x solution for 30 seconds and 
then removed and the cells placed at 37°C for 3-5 minutes for cell detachment. 
Cells were resuspended in 5 mL fresh media before cell counting. Cells were 
maintained between 3 x 105 and 1 x 106 cells/mL in 75cm2 flasks at 37°C and 5% CO2 
and were routinely passaged every 3-4 days between passage 90-120. 
 
2.2.1.3.2 NCI-H292 
NCI-H292 were purchased from ECACC and are derived from a cervical node 
metastasis of pulmonary mucoepidermoid carcinoma of a 32 year old female 
(ECACC). They were originally used for its ease of viral transfection (194) though 
 60 
there are many studies now on this cell line particularly with respect to mucin 
production. 
NCI-H292 were cultured in the same media as A549 and using the same procedure. 
Cells were maintained between 3 x 105 and 1 x 106 cells/mL in 75 cm2 flasks at 37°C 
and 5% CO2 and were routinely passaged every 3-4 days between passage numbers 
11-30. 
 
2.2.1.3.3 16HBE14o- 
16HBE14o- cells were obtained from Dr. Gruenert from the University of California, 
San Francisco USA. 16HBE14o- are derived from SV-40 transformation of cells 
obtained from human bronchial epithelium (22, 195). 16HBE14o- were cultured in 
MEM containing 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, 
and 10% FCS. T75 flasks were pre-coated with 2 mL of fibronectin coating solution 
(see appendix) overnight and stored at room temperature before use. At 80-90% 
confluency, cells were passaged by firstly washing with hepes buffered saline (HBS) 
followed by addition of 5 mL 0.25% trypsin EDTA 1x solution for 30 seconds. Trypsin 
was then removed and the cells placed at 37°C for 3-5 minutes for cells to lift off 
the flask and then resuspended in 5 mL fresh media before cell counting. Cells were 
used between passage number 11-33, maintained at 37°C and 5% CO2 and were 
routinely passaged every 3-4 days. 
 
2.2.1.3.4 SAEC 
Human small airway epithelial cells (SAEC) were purchased from Lonza and 
certificate of analysis stated they were derived from a 6 year old male, tissue 
acquisition number 14289. SAEC were cultured in small airway cell basal medium 
500 mL (SABM) containing the small airway cell growth medium SingleQuot kit 
supplements and growth factors at the following volumes: bovine pituitary extract 
2 mL, epinephrine 0.5 mL, gentamicin sulfate amphoterin-B 0.5 mL, 
triiodothyronine T3 0.5 mL, retinoic Acid 0.5 mL, bovine serum albumin (BSA) fatty 
acid free 5 mL, insulin 0.5 mL, human recombinant epidermal growth factor in 
buffered BSA solution 0.5 mL, transferrin 0.5 mL, and hydrocortisone 0.5 mL 
(Lonza). 
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At 80-90% confluency, SAEC were passaged by washing with 5 mL HBS followed by 
addition of primary cell TE and visualising the cells under the light microscope to 
determine when they are detached (around 2 minutes) and then trypsin 
neutralising solution was added immediately. Cells were maintained at 37°C and 5% 
CO2 between 4 x 10
5 – 1 x 106 cells/mL and used between passages 1-3. Media was 
changed every other day. 
 
2.2.1.4 Cell enumeration and viability 
Epithelial cells were diluted 1/2 with 0.4% trypan blue solution and 10 µL was 
added onto a Neubauer haemocytometer (Thermofisher Scientific) and viewed with 
a light microscope. For cell enumeration, cells were counted in each of the four 1 
mm corner squares illustrated in the diagram below (Sigma Aldrich). Cells on the 
outer edge were counted only on the top and left side lines and not the bottom and 
right. Each corner square of the haemocytometer represents 0.1 mm3 which is 
equal to 10-4cm3. As 1 cm3 is equal to 1 mL the average cell count x dilution factor x 
104 gives the number of cells/mL. 
 
Trypan blue dye only enters cells in which the 
membrane is not intact and therefore the cells 
are not viable. In order to calculate cell 
viability the number of blue stained cells is 
divided by the total number of cells and 
multiplied by 100 to represent a percentage. 
 
 
 
2.2.1.5 Cryopreservation  
Before freezing, cells were counted as above. 
-2.2.1.5.1 A549 and NCI-H292  
Cell freezing media was produced from making a solution of filter sterilised FCS with 
10% DMSO. 2-5 x 106 cells were put into a falcon tube and centrifuged at 2,000 rpm 
for 5 minutes to form a cell pellet. The supernatant was removed and the cell pellet 
was resuspended in 1 mL freshly made freezing media and transferred to a cryovial 
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which was placed on ice and frozen slowly in an insulated container. Cryovials were 
placed into -80°C for at least a day before transferring to liquid nitrogen. 
 
-2.2.1.5.2 Cryopreservation of 16HBE14o- 
The same procedure to that above was used however the cell freezing media 
consisted of 50% FCS, 40% MEM and 10% DMSO. 
 
-2.2.1.5.3 Cryopreservation of SAEC 
The same procedure to that above was used however the cell freezing media 
consisted of 80% SABM, 10% FCS and 10% DMSO. 
 
2.2.1.6 Cell stimulations 
Before addition of any stimulus, cells seeded in tissue culture plates were rested for 
at least 18 hours. 
2.2.1.6.1 LPS 
LPS was made up in RPMI 1640 media by vortexing for 3 minutes, heating at 37°C 
for 10 minutes, vortex for 3 minutes and split into aliquots stored at -20°C with the 
current vial stored at 4°C to avoid freeze thaw cycles, at a 1 or 5 mg/mL stock. LPS 
was further diluted in media to use at a final concentration of 10 µg/mL. 
2.2.1.6.2 TNFα 
Human recombinant TNFα was reconstituted in PBS at 10 µg/mL stock solution and 
aliquoted into eppendorfs stored at -80°C. TNFα was further diluted in media to a 
final concentration of 10 ng/mL in cell stimulations. 
2.2.1.6.3 Vitamin D 
1,25 dihydroxyvitamin D3 (1,25(OH)2 D3)  was reconstituted in DMSO and kept at a 
stock concentration of 1 x 10-4 M. Aliquots were made in amber screw cap glass 
vials and stored at -80°C. For use, 1,25(OH)2 D3 was further diluted in media to a 
final concentration of 1 x 10-7 to-10 M for experiments with a final concentration of 
DMSO ≤0.1% to ensure no adverse effects on the cells. 
 
2.2.1.6.4 Inhibitors  
LY294002, SB203580, PD98059, MG132, and SP600125 were reconstituted in DMSO 
at stock concentrations of 10-100 mM and split into aliquots protected from light 
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and stored in -20°C. Y27632 was reconstituted in PBS. Inhibitors were further 
diluted to a final concentration of  0.1-10 µM in cell culture media. 
 
2.2.1.6.5 tBHP and H2O2 
Both tBHP and H2O2 were diluted in PBS from stock solutions to a concentration of 
400 mM and then further diluted in cell culture media for a final concentration of 
100-400 μM. 
 
2.2.2 Nucleic Acid Isolation 
2.2.2.1 RNA extraction using Tri-reagent 
Tri-Reagent solution was used to lyse and extract RNA from cell lines according to 
the manufacturer’s instructions. The method is one of phase separation where the 
RNA separates into the aqueous phase on addition of BCP and then is precipitated 
out with 2-propanol and finally washed with ethanol.  
Briefly, 1 mL/well Tri-reagent was added to cells cultured in a 6 well plate and 
incubated for 5 minutes at room temperature before harvesting into eppendorfs 
and then stored at -80°C. Following thawing, 100 µL BCP was added to each tube, 
shaken for 10 seconds and then incubated at room temperature for 10 minutes. 
Tubes were then centrifuged at 12,000 x g for 20 minutes at 4°C. The aqueous 
phase was transferred to a fresh tube and 500 µL 2-Propanol was added to each 
tube, vortexed for 10 seconds then incubated at room temperature for 10 minutes. 
Tubes were then centrifuged at 12,000 x g for 15 minutes at 4°C and the 
supernatent was removed from the pellet. 1 mL 70% ethanol was added to each 
tube and then centrifuged at 12,000 x g for 10 minutes. The ethanol was removed 
and the pellet was allowed to air dry for 10 minutes. Isolated RNA was solubilised in 
20-100 µL nuclease free water and stored at -80°C for at least one night before RNA 
quantification. 
 
2.2.2.2 RNA quantification 
UV spectroscopy can be used to quantify the concentration of RNA within a given 
sample. The Nanodrop 1000 spectrophotometer from Thermofisher Scientific 
enables quantification of RNA within just 1 µL of sample from and therefore 
provides and quick and easy method of quantification. 
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The concentration can be calculated using the Beer Lambert law: 
A = εcl 
A = absorbance in arbitary units 
ε = extinction coefficient 
c = concentration (M) 
l = path length in cm  
 
It is known that the extinction coefficient of RNA is 0.025 (mg/mL)-1 cm-1 (Ambion) 
and that an absorbance reading of 1 at 260 nm is ~40 µg/mL single stranded RNA 
therefore the software is able to calculate the quantity of RNA within a given 
sample. 
Absorbance readings at 230, 260 and 280 nm are taken and the ratio of 260/280 
and 260/230 are an indicator of RNA purity with values 1.8-2.0 considered as 
purified RNA. 
 
2.2.3 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
2.2.3.1 cDNA synthesis from RNA extracts 
50-100 ng/µL RNA produced from Tri-reagent extraction was used to synthesise 
cDNA using Taqman Reverse Transcriptase Reagents as per manufacturer’s 
instructions (see appendix). These were run on a PTC-100 Peltier Thermal Cycler for 
10 minutes at 21°C, 15 minutes at 42°C, 5 minutes at 99°C and 5 minutes at 4°C. 
cDNA was then diluted with 15 µl H2O before use. 
 
2.2.3.2 cDNA synthesis directly from cell cultures 
Primary SAEC do not grow well in culture and it is difficult to produce enough cells 
to seed in a 6 well plate for experiments and therefore difficult to extract enough 
RNA for PCR. An alternative method for extracting RNA to cDNA in a few steps in 
cells grown in a 96 well plate was used for SAEC (see appendix).  Briefly, cells were 
washed twice in ice cold PBS before addition of 30 µL cells to cDNA lysis buffer and 
transferred into 0.2 mL PCR tubes. Lysates were incubated at 75C for 15 minutes 
and then frozen until required. On use 1 µL DNase 1 and 3 µL 10 x DNase 1 buffer 
was added to each sample and incubated at 37C for 15 mins and then 75C for 5 
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mins. From this stock of DNase treated RNA, 8 µL was transferred to a fresh tube 
and the rest was frozen for future use. 
1 µL of random hexamers and 3 µL dNTPs was added to each sample and then 
incubated at 75C for 5 minutes. A mastermix of reagents was made comprising the 
following volumes per sample; 4 µL 5 x RT buffer, 2 µL 0.1M DTT, 1 µL ddH2O, 0.5 
µL MMLV reverse transcriptase enzyme and 1 µL RNase inhibitor and then 8.5 µL 
was added to each sample followed by incubation at 37C for 50 minutes and 75C 
for 15 minutes. 
This cDNA was diluted with 30 µL of H2O before use for qRT-PCR. 
 
2.2.3.3 qRT-PCR 
5 µL cDNA (produced from either of the above methods) and 15 µL SYBR green 
mastermix was used to quantify gene expression as per the manufacturer’s 
instructions (see appendix) on a Qiagen Q10 RT-PCR detection system using the 
following cycles: 1 cycle of 2 minutes at 95°C, then 40 cycles of 15 seconds at 95°C 
and 40 seconds at 60°C, followed by a melting analysis ramping from 60°C to 94°C 
to determine primer dissociation curves (see appendix). 
 
2.2.3.4 Primer design 
Primers were designed using the Roche Universal Probe library (www.roche-
applied-science.com/sis/rtpcr/upl/ezhome.html) which automatically blasts target 
nucleotide sequences in PubMed to identify sequences which give a single product 
to avoid unspecific binding and primer dimers. Amplicons were 50-120 base pairs in 
length with primers of 18-22 bases in length, a 50% G/C content and spanned an 
intron-exon boundary to prevent replication of genomic DNA. 
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2.2.3.5 Analysis 
Gene expression was quantified from a standard curve (see appendix) giving 
copies/reaction of mRNA and then made relative to Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), a house keeping gene. Fold change was calculated from 
the 0 values. Efficiencies of reaction were all over 0.75 and R2 was always ≥0.99.  
 
2.2.4 ROS assay   
2, 7’-dichlorodihydrofluoresceindiacetate (H2DCFDA) is a compound which is taken 
up by cells and converted into further intermediates by cellular esterases. In the 
presence of intracellular ROS the intermediate is irreversibly converted into the 
fluorescent compound 2’,7’-dichlorofluorescein (DCF) which is detectable using a 
simple microplate based assay. 
 
2.2.4.1 Method optimisation: 
Different methods have been employed to determine ROS using this compound 
including flow cytometry. However, with adherent cells in particular the sheer 
stress of trypsinisation for use in suspension is a cellular stress. Microplate methods 
have been used in the literature but the exact method is either left out or vague. 
For optimisation in the respiratory system a number of these methods were tested  
as described in Chapter 5.  
2.2.4.2 Optimised assay procedure 
H2DCFDA was made up fresh in DMSO at a stock of 10 mM and then further diluted 
in PBS to a final concentration of 10 µM so that the concentration of DMSO is 0.1% 
and did not have any detrimental effect on the cells. NCI-H292 and A549 cells were 
plated at 4,000 cells per well on a 96 well flat clear bottomed black sided 
fluorescence plate and grown to 80% confluency (2-3 days). Any pre-incubations 
with vitamin D were carried out in this time. Cell media was removed and cells 
washed with 100 µL PBS before addition of 100 µL 10 µM H2DCFDA for 40 minutes. 
The H2DCFDA was then removed and replaced with 100 µL phenol red free media 
for 20 minutes to allow cell recovery. Before addition of ROS inducing stimulus, 
fluorescence was measured on the on POLARstar OPTIMA microplate reader (BMG 
Labtech) with absorbance at 485 nm and emission at 520 nm.  
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2.2.5 Cytotoxicity / Proliferation Assay 
NCI-H292 and A549 cells were plated at 4,000 cells and 16HBE14o- 10,000 cells per 
well on a 96 clear bottom and sided microplates and grown to 80% confluency (2-3 
days). Any cell treatments were carried out in this time. 20 µl Cell Titer 96 AQueous 
One Solution Reagent (MTS) was added to each well, incubated in the dark and 
absorbance read at 490 nm 1 hour (A549) or 3 hours (NCI-H292/16HBE14o-) later 
on POLARstar OPTIMA microplate reader. The solution contains MTS tetrazolium 
compound which is reduced by living cells into a coloured formazan product soluble 
in tissue culture medium. The quantity of formazan is measured by absorbance and 
is directly proportional to the number of living cells. For statistical analysis the 
control of cells alone with DMSO was taken as 100% cell proliferation.  
 
2.2.6 Protein Detection 
 
2.2.6.1 Western Blotting 
2.2.6.1.1 Extract Preparation 
Supernatants from cells in 6 well plates were removed and 200 µL 1:1 PBS: 2x SDS 
buffer was added to each well. Cells were scraped into eppendorf tubes and 
covered with parafilm before boiling samples for 5 minutes. Extracts were kept at -
80°C until required. For gel loading, samples were reboiled and 18 µL of each 
sample was mixed with 2 µL of sample reducing agent and the 20 µL added to each 
well. 
 
2.2.6.1.2 SDS-PAGE  
Pre-made NuPAGE 4-12% Bis-Tris gel were rinsed with deionised (di) H2O, and the 
gel foot tape and comb were removed. The gel was inserted into the XCell SureLock 
Mini-Cell rig (Invitrogen). 1 x running buffer (appendix) was added to the upper and 
lower chambers, and 500 µL NuPAGE antioxidant to the upper buffer chamber. 
Wells of the gel were rinsed out using the running buffer. 5 µL of molecular weight 
marker and 20 µL of sample was added to each well. The gel was run at 200 V for 50 
minutes. 
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2.2.6.1.3 Gel Transfer 
PVDF membrane was pre-soaked in methanol for 30 seconds and then 1 x transfer 
buffer for at least 15 minutes before transfer. Blotting pads were soaked in 1 x 
transfer buffer before transfer. The membrane was placed on the back of the gel 
with soaked filter paper sandwiching either side and then put in the XCell II Blot 
Module transfer rig (Invitrogen) with the gel closest to the cathode and membrane 
closest to the anode. The transfer chamber was filled with 1 x transfer buffer and 
the lower chamber with diH2O. The transfer was run at 30V for 1 hour. 
 
2.2.6.1.4 Gel staining 
Following transfer the gel was rinsed for 3 x 5 minutes in diH2O before staining with 
20 mL Simply Blue safestain for 1 hour and then washed for 1 hour in diH2O and 
kept for imaging on G-box imager Syngene (Cambridge, UK). 
 
2.2.6.1.5 Immunoblotting 
Following transfer the membrane was placed in blocker (appendix) for 1 hour at 
room temperature with agitation. Primary antibody was diluted in blocker and 
incubated with the membrane for 1 hour at room temperature. The membrane was 
then placed in blocker for 3 x 5 minutes and then washed for 3 x 5 minutes with 
TBST (appendix). HRP conjugated secondary antibody was diluted in blocker and 
incubated with the membrane for 30 minutes at room temperature followed by 
blocking again 3 x 5 minutes in blocker before washing in TBST for 3 x 5 minutes. 
Antibodies were diluted in blocker (volume/volume): 
Rabbit monoclonal anti-Nrf2 antibody 1/750  
Goat anti rabbit HRP antibody 1/1000  
Anti-β-actin mouse monoclonal antibody 1/100,000 
Polyclonal goat anti-mouse HRP antibody 1/1000  
  
2.2.6.1.6 Chemiluminescence 
RapidStep ECL reagent is a substrate for the horse radish peroxidase enzyme which 
is conjugated to the secondary antibody and incubation for 1 minute allows 
conversion of the substrate to luminescence which can be measured by traditional 
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incubation with film or by imaging on G-box imager. Semi-quantitative data was 
collected by measuring densitometry using image J software. 
 
2.2.6.1.7 Reprobing 
Antibodies were stripped off the membrane using Re-blot Plus antibody stripping 
solution. The membrane was incubated in 10% Re-blot solution in H2O with gentle 
agitation for 30 minutes then washed for 2 x 5 minutes in blocker. Then the 
membrane was treated with primary antibody and the same protocol was followed 
for immunoblotting (2.2.6.1.5). 
 
2.2.6.2 Flow Cytometric Bead Array 
This method was carried out according to manufacturer’s instructions. Standards 
were reconstituted in 2 mL assay diluent and allowed to equilibrate for 15 minutes. 
A serial dilution of the standards was performed using 300 µL 1:1 with assay diluent 
from 1:2 to 1:256. Each cytokine capture bead was mixed together using 10 µL of 
each per test sample and mixed. To each tube 50 µL of capture beads, 50 µL of 
human inflammatory cytokine PE detection reagent, and 50 µL of standard dilutions 
or unknown samples was added. Assay tubes were incubated for 3 hours at room 
temperature protected from light. 1 mL of wash buffer was added to each assay 
tube and centrifuged at 200 g for 5 minutes. The supernatant was aspirated and the 
pellet resuspended in 200 µL of wash buffer. Samples were run on the BD FACSAria 
II flow cytometer with 4 lasers (blue 488 nm, red 633 nm, violet 405 nm and near 
UV 375 nm). 
 
2.2.6.3 Gelatin Zymography 
In this technique, proteins are separated according to their molecular weight as in 
western blotting but the gel is incubated for 24 hours to allow any active 
gelatinases to degrade the gelatin within the gel. On staining of the gel for protein 
there are clear areas where the enzymes have degraded the gelatin and this can 
qualitatively show the presence of gelatinase but these bands can also be analysed 
for their intensity on imaging and therefore semi-quantitative assessment can also 
be performed. 
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2.2.6.3.1 Gel preparation 
Porcine gelatin was dissolved in ddH2O at 65°C and then cooled to room 
temperature. 
All resolving gel ingredients (see appendix) were combined and poured between 
glass gel plates. Isopropanol was added on top of the gel to make it air-tight. The 
gel was allowed to polymerise at room temperature for 30-60 minutes before 
removal of the isopropanol and rinsing the top of the gel with ddH2O to remove any 
residue. 
 
All stacking gel ingredients (see appendix) were mixed together and poured on top 
of the set resolving gel and a gel comb was placed between the glass plates. 
The gel was allowed to polymerise for 30 minutes. 
 
2.2.6.3.2 Extract preparation 
Samples were diluted 3:1 with loading buffer (appendix) with and without EDTA for 
the control gel. EDTA inhibits metalloproteinase activity by blocking the zinc active 
site. 10 µL of each sample was added to wells and 5 µL of molecular weight marker 
or MMP9 control. The gel was run at 150V for 120 minutes or 30 minutes after the 
dye had run off the bottom of the gel.  
The normal gel was placed in rinse buffer (appendix) and the EDTA control gel in 
rinse buffer + EDTA for 2 x 15 minutes on a shaker. Gels were then incubated 
with/without EDTA in incubation buffer (appendix) at 37°C for 24 hours to allow the 
enzymes to activate and proteolytically degrade the gelatin within the gel. The gels 
were then rinsed in dH2O and stained with staining solution (appendix) overnight to 
stain all the protein within the gel. The gel was then destained with destain solution 
(appendix) for up to one hour until the degraded areas are clear. Gels were then 
imaged on the G-box imager and semi-quantitative data was collected by 
measuring densitometry using image J software. 
 
2.2.6.4 ELISA 
NCI-H292 were grown in 6 well plates and untreated or treated with TNFα, LPS or 
PMA for 24 hours before harvesting supernatents. 50 μL of each sample 
supernatent in duplicate were left to dry in 96 well ELISA plate overnight at 42°C. 
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Wells were then blocked with 2% BSA for 1 hour and then washed 3 x 5 minutes in 
PBS containing 0.05% Tween 20. Wells were incubated with 1/100 primary mouse 
anti-MUC5AC antibody in PBS for 1 hour followed by 3 x 5 minute washes in 0.05% 
Tween 20. Secondary goat anti-mouse HRP at 1/1000 dilution in PBS was then 
added and incubated for a further hour.  The plate was washed 5 times with 0.05% 
Tween 20 and colorimetric reaction was developed with 100 μL mix of 1:1 
tetramethylbenzine (TMB substrate) and hydrogen peroxide for 20 minutes before 
stopping the reaction with 50 µL H2SO4 and reading absorbance at 450 nm on the 
POLARstar OPTIMA microplate reader. 
 
2.2.6.5 Immunohistochemistry for MUC5AC expression 
NCI-H292 and A549 cells were grown on cover slips in 6 well plates. Supernatents 
were removed and cells washed with PBS. Cells were fixed with 4% 
paraformaldehyde for 15 minutes. Cover slips were washed 3 x 5 minutes in PBS 
and cells were blocked in goat quench (appendix) for 10 minutes. Cells were then 
permeabilised with 0.2% Triton X-100 for 20 minutes and then stained with 1/100 
mouse anti-human MUC5AC clone 45M1 antibody diluted in blocking buffer 
(appendix) and then washed 3 x 5 minutes in wash buffer (appendix) before 
addition of secondary goat anti-mouse Alexafluor 488 nm at 1/1000  diluted in 
blocking buffer (appendix). Cover slips were washed 3 x 5 minutes in washing buffer 
and then cell nuclei were stained with 1/100 DAPI in PBS for 15 minutes before a 
final vigorous wash with PBS 3 x 5 minutes. Cover slips were mounted on slides with 
5 µL Fluoromount G. Images were taken on Zeiss Axioplan II microscope using 
Axiovision software.  
 
2.2.7  Statistical analysis 
All graphs were produced using GraphPad Prism 5 and the mean plus the standard 
error mean were plotted. Unless otherwise stated, each data set were made 
relative to their individual controls by dividing each value by the average of the 
control values, so that in the end the average control value was 100% or 1-fold.  
Where data from different cell types is presented on the same graph each is 
relative to its own control so that differences between the cell types could be 
compared directly. Students t-test was carried out using GraphPad Prism and 
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Microsoft Excel to compare the means of test against controls. One-way ANOVA 
with Tukey’s multiple comparison test was used to compare different treatment 
conditions to each other and controls. Two-way ANOVA with Bonferroni post-test 
was used to compare kinetic induction patterns of the same mediators between the 
different cell types and also different cellular treatments. 
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Chapter 3: 
 
Characterisation of airway epithelial cells 
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3.1  Introduction 
The lung is constantly exposed to noxious agents and pathogens from the external 
environment in the process of inhalation.  Airway epithelial cells provide an 
important barrier to these external stimuli and this layer is constantly shedding and 
renewing to avoid damage from exposure to potentially carcinogenic particles such 
as cigarette smoke. The cells are protected by a mucous layer which when damaged 
allows interaction with pathogens and other environmental stimuli, activating the 
airway epithelial cells to initiate an immune response with leukocyte infiltration 
(196). 
There are a wide range of airway epithelial cell lines with which to study airway 
inflammation, some more widely characterised than others. In this study three 
widely studied cell lines were used along with primary small airway epithelial cells 
(SAEC) to compare the basal and inducible expression of inflammatory mediators. 
The SAEC were the most physiologically relevant cell type used however, these are 
expensive and difficult to culture. Therefore it was investigated whether more well 
characterised cell lines would express similar mediators and therefore be useful 
models of airway inflammation. The A549 adenocarcinoma cell line is the most 
widely characterised airway epithelial cell line and has been described by some to 
be a model of alveolar type II cells (197), although it is now mostly studied for its 
cancerous properties. The NCI-H292 cell line is derived from a mucoepidermoid 
carcinoma shown to be like the SAEC in their response to cigarette smoke (198) and 
are more extensively studied for their mucous producing properties (21). The 
16HBE14o- is a virally transformed immortalised bronchial epithelial cell line which 
has been widely used to study epithelial barrier function and ion transport and are 
similar to primary bronchial epithelial cells (22, 195). These three cell lines have not 
been directly compared previously. 
In this study the expression of pro-inflammatory mediators important in COPD 
pathology namely IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNFα, ICAM1, TGFβ1, MMP1, 
MMP9, MMP12 and MUC5AC were compared for all tested cell types to identify a 
cell line model of SAEC to then investigate the effects of vitamin D in further 
studies. Many groups have investigated the effects of cigarette smoke on 
inflammatory gene expression in airway epithelial cells which is prominent in the 
pathology of COPD (199). However, other important factors can activate an 
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inflammatory response and have been implicated in this disease. Therefore, 
Pseudomonas aeruginosa LPS, a key pathogen in COPD exacerbations known to 
activate airway inflammation, and TNFα one of the most important factors in COPD 
pathology, were used to study their effect on inflammation in airway epithelial 
cells. 
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3.2  Aims of study 
 To characterise the mRNA and protein expression of inflammatory 
mediators in primary human small airway epithelial cells and three 
commonly used human airway epithelial cell lines. 
 To compare the expression of mediators between the different cell types to 
identify a robust cell line model to use in future studies 
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3.3  Results 
3.3.1 Morphology of the cell lines used in this study 
The cell lines used in this study were derived from different lung locations with 
primary small airway epithelial cells and the A549 cell line from the small airways, 
and the NCI-H292 and 16HBE14o- cells from the bronchi. Also, the cell lines have 
different transformation properties with the 16HBE14o- SV-40 virally transformed 
for immortalisation, and the A549 and NCI-H292 both being cancerous cell lines. 
This enabled airway epithelial cells with different cellular characteristics to be 
compared in their inflammatory gene and protein expression patterns. 
Figure 3.1 shows the morphology of the different cells used in the study. The A549 
are the closest in morphology to the SAEC, both being alveolar in origin with 
stretched migratory behaviour congregating in groups and forming a cobblestone 
like appearance. However, the A549 have different growth characteristics with a 
greater doubling time than the SAEC. Both the NCI-H292 and 16HBE14o- appear 
different to alveolar cells and to each other despite both being of bronchial origin. 
Both are more rounded in morphology than the alveolar cells and tend to clump 
together in groups which then expand towards other colonies rather than migrate. 
The NCI-H292 cells also have a greater doubling time than the 16HBE14o- cells, 
likely due to their malignant properties. 
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3.3.2 Expression of inflammatory mediators in airway epithelial cells 
To study the basal mRNA and protein expression of different mediators SAEC, 
16HBE14o-, A549 and NCI-H292 cells were plated out and left to grow to 
confluency. Supernatants were removed to measure secreted proteins and cells 
were lysed, RNA extracted, cDNA made and used for qRT-PCR to study mRNA 
expression. The inflammatory mediators tested were those that relate to COPD 
pathology, namely: IL-1β, IL-6, IL-8, TNFα, TGFβ1, ICAM1, MUC5AC, IL-10, IL-12p70, 
MMP1, MMP9 and MMP12.  
Table 3.1 demonstrates that all the cell types tested expressed very similar basal 
levels of mRNA for IL-1β, IL-6, IL-8, TNFα, TGFβ1, MMP1, MMP9 and MMP12. IL-10 
and IL-12p70 mRNA were not detected in any cell type. ICAM1 mRNA was detected 
in all but the 16HBE14o- cells. Basal MUC5AC mRNA was expressed in the NCI-H292 
and A549. 
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Where possible the protein expression of mediators was also tested as 
demonstrated in Table 3.2. Protein expression of cytokines IL-1β, IL-6, IL-8, IL-10, IL-
12p70 and TNFα in cell supernatents was detected using a flow cytometric bead 
array. The key proteins expressed by all of the cell lines were IL-6 and IL-8. IL-1β was 
also found to be expressed at low levels in the SAEC but not by the NCI-H292 cell 
line which was also tested. IL-10, IL-12p70 and TNFα protein was not shown to be 
expressed basally in any of the cells lines tested. 
The basal expression of MMP9 protein has been shown previously in A549, NCI-
H292 and SAEC (42, 200, 201), however not in the 16HBE14o- cells. Using gelatin 
zymography, MMP9 enzyme activity was detected in the 16HBE14o- cells.  
By developing a MUC5AC ELISA, basal protein secretion was detected in the A549 
and NCI-H292 cells. 
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3.3.3 Induction of inflammatory mediators by Pseudomonas aeruginosa LPS 
Gram negative bacteria are important in the pathophysiology of several chronic 
airway diseases and infection leads to worsening of disease symptoms and chronic 
inflammation (202). Pseudomonas Aeruginosa is one of the most common bacterium 
isolated in exacerbations of COPD (10). An important virulence factor for this 
bacterium is LPS found in the outer layer of the bacterial cell membrane. The 
receptor for LPS is TLR4 which is expressed on the airway epithelial surface (202). 
Firstly, the cellular response to LPS treatment was studied in terms of induction of 
mRNA for inflammatory mediators. Then, the kinetics of mRNA expression in the 
different cell lines were compared to find a time point with which to target the 
maximal mRNA induction with vitamin D treatment in future studies. 
Primary small airway epithelial cells, 16HBE14o-, NCI-H292 and A549 cells were 
treated with 10 μg/mL Pseudomonas Aeruginosa LPS for up to 24 hours and the 
kinetics of pro-inflammatory mediators IL-1β (A), IL-6 (B), IL-8 (C), TNFα (D), TGFβ 
(E) and ICAM1 (F) were quantified using qRT-PCR as shown in Figure 3.2. 
Surprisingly, the induction kinetics between the different cell lines was quite 
different showing different sensitivities to LPS treatment. None of the cell lines had 
a significant induction of TGFβ1 mRNA on LPS treatment. 
In the SAEC, with 1 hour of LPS treatment there was a significant induction of IL-1β 
(p<0.01), IL-6 (p<0.05), IL-8 (p<0.001), TNFα (p<0.001), and ICAM1 (p<0.05) mRNA 
expression, with a prolonged significant induction up to 4 hours for IL-8 (p<0.01) 
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and ICAM1 (p<0.05). The 16HBE14o- cell line was not sensitive to LPS treatment at 
the concentration used in this study with no significant induction of IL-1β, IL-6, IL-8, 
TNFα, or TGFβ1 at any time point 0-24 hours. ICAM1 mRNA was not found to be 
expressed basally in the 16HBE14o- cell line (Table 3.1) and was not found to be 
induced on LPS treatment and therefore is not depicted in Figure 3.2F. 
The NCI-H292 cell was the most sensitive to LPS treatment with the greatest fold 
induction of at least ~10 fold for all the mediators tested (Figure 3.2). All were 
significant at 1-4 hours (p<0.001) with a large induction, which then tailed off with 
IL-1β, IL-6, IL-8, TNFα and ICAM1 all showing the same kinetic pattern of induction 
suggesting they are being regulated in the same way.  A different kinetic pattern of 
induction was seen in the A549 cell line with increasing induction between 1-4 
hours giving a significant induction of IL-8 at 4 hours (p<0.001) and TNFα at 1 hour 
(p<0.05) and then a later induction of ICAM1 (p<0.05), IL8 (p<0.001) and IL-1β 
(P<0.05).  
All of the cell lines tested were significantly different to the SAEC for concentrations 
of each cytokine at one or more time points via two-way ANOVA. However, the 
induction kinetics of IL-1β, IL-6, IL-8, TNFα and TGFβ1 between the NCI-H292 and 
the SAEC were similar suggesting they may be a useful model in future studies 
(Figure 3.2). 
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3.3.4 Induction of mRNA expression for inflammatory mediators by TNFα 
TNFα plays a central role in the initiation and maintenance of inflammatory 
responses in the lung and has been found to be elevated in sputum, breath 
condensate and the systemic circulation in patients with COPD (6, 7). It has also been 
shown to be responsible for 70% of cigarette induced airspace enlargement and 
inflammatory cell influx in mice (29). The main source of TNFα is alveolar 
macrophages and its expression is enhanced by infection. Airway epithelial cells 
have been shown to secrete the important neutrophil chemoattractant IL-8 in 
response to TNFα treatment (203). 
As in the previous section, the kinetics of mRNA induction for inflammatory 
mediators was compared in the different cell lines but in response to TNFα 
treatment. A concentration of 10 ng/mL was used as this is widely used in the 
literature to induce an inflammatory response (204). 
SAEC, 16HBE14o-, NCI-H292 and A549 cells were treated with 10 ng/mL TNFα for 
up to 24 hours and the kinetics of IL-1β (A), IL-6 (B), IL-8 (C), TNFα (D), TGFβ1 (E) 
and ICAM1 (F) was quantified using qRT-PCR, shown in Figure 3.3. 
Similarly to LPS treatment, the highest induction of cytokine mRNA tested occurred 
at 1 hr although interestingly the cell lines were more similar in their induction 
kinetics in response to TNFα treatment and this treatment gave a more prolonged 
induction of mRNA than the LPS treatment. 
At 1 hr, TNFα induced significant expression of IL-6 (p<0.01), IL-8 (p<0.001) and 
TNFα (p<0.001) mRNA in the SAEC, but IL-1β expression although increased at 1 
hour was not found to be significant (Figure 3.3). This was similar in the 16HBE14o- 
with the 1 hour of TNFα treatment inducing significant expression of IL-1β (p<0.05), 
IL-6 (p<0.001), IL-8 (p<0.01) and TNFα (p<0.001) mRNA, and also in the NCI-H292 
cells a significant induction of IL-1β (p<0.001), IL-6 (p<0.001), IL-8 (p<0.001), TNFα 
(p<0.001) and ICAM1 mRNA (p<0.001). In the SAEC, ICAM1 showed different 
kinetics of induction with 8 hour TNFα treatment giving the peak induction of 
ICAM1 mRNA (p<0.05). 
The A549 were the most responsive to TNFα treatment in terms of the greatest fold 
induction over basal with over ~ 100 fold induction of IL-6, IL-8 and TNFα mRNA 
expression. However, the kinetics differed from the other cell lines with 4 hrs giving 
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the greatest significant induction of IL-1β (p<0.01), IL-6 (p<0.001), IL-8 (p<0.001), 
TNFα (p<0.001) and ICAM1 (p<0.001) (Figure 3.3).  
Similarly to LPS treatment, TNFα treatment did not induce TGFβ1 mRNA expression 
in any of the cell types tested. 
For TNFα induction of IL-1β, IL-6, IL-8, and TNFα mRNA the 16HBE14o- and NCI-
H292 cells were not significantly different to the SAEC by two-way ANOVA and 
therefore may be useful models of inflammatory gene expression for future studies. 
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3.3.5  Induction of inflammatory cytokine protein expression by TNFα 
A flow cytometric bead array was used to investigate the TNFα induction of IL-1β, 
IL-6, IL-8, IL-10 and IL-12p70 in the different cell lines. IL-6 and IL-8 were the key 
cytokines induced by TNFα treatment (Figure 3.4). This matches the data on basal 
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protein expression where IL6 and IL8 were the key proteins expressed by the airway 
epithelial cells (Table 3.2). 
TNFα significantly upregulated IL-6 secretion in the NCI-H292 (p<0.05) and SAEC 
(p<0.001) (Figure 3.4). However, IL-8 protein expression was significantly 
upregulated by TNFα in the A549 (p<0.05), NCI-H292 (p<0.05) and the SAEC 
(p<0.001) but not in the 16HBE14o- cells (Figure 3.4). The SAEC had the second 
greatest expression of both these cytokines and therefore the greatest expression 
of IL-6 and IL-8 combined. This suggests that they may be more sensitive to 
treatment with TNFα than the three cell lines tested. 
 
 
 
3.3.6  Induction of MMPs and MUC5AC mRNA expression by TNFα 
Since TNFα induced similar cytokine expression in the different cell types, it was 
investigated if the same would be true for MMP and MUC5AC expression. MMPs 
are important in the remodelling processes within the lung but overexpression in 
COPD leads to destruction of the alveolar spaces. MUC5AC is also an important 
airway secretion protecting the epithelial layer. However, in COPD goblet cell 
hyperplasia and hypersecretion leads to overproduction of MUC5AC and airway 
obstruction. In this study the TNFα induction of MMPs 1 (A), 9 (B) and 12 (C) and 
MUC5AC (D) mRNA expression were investigated, shown in Figure 3.5.  
TNFα induced MMP1 mRNA expression in A549 and NCI-H292 cells, with a 
significant induction at 8 hr in A549 (p<0.001) and 16 hr in both A549 and NCI-H292 
(p<0.01, p<0.05) respectively (Figure 3.5).  
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TNFα induced MMP9 mRNA expression in all the cell lines, with a significant 
induction of MMP9 mRNA at 16 hr in the SAEC (p<0.05), A549 (p<0.001) and NCI-
H292 (p<0.001) (Figure 3.5). However, the kinetics were different in the 16HBE14o- 
with a significant induction at 8 hours of TNFα treatment (p<0.001) (Figure 3.5). For 
MMP9 expression, the 16HBE14o- and NCI-H292 cells were not significantly 
different from the SAEC by two way ANOVA. 
Interestingly, MMP12 was significantly induced by TNFα in the SAEC, peaking at 8 hr 
(p<0.01), but not in any of the other cell lines (Figure 3.5). 
TNFα induction of MUC5AC mRNA expression was studied in the SAEC, 16HBE14o- 
and NCI-H292 but was only detected in the NCI-H292 cell line with a significant 
induction at 16 hours (p<0.01) (Figure 3.5). 
 
 
 
 
 89 
3.3.7  MMP9 functional activity 
TNFα induced MMP9 enzyme activity in the SAEC at 24 hr (p<0.001) shown in 
Figure 3.6. TNFα had little effect on MMP9 in the 16HBE14o- cells but there was a 
much higher basal expression (around 5 fold) of MMP9 in this cell line than the 
SAEC. 
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3.3.8  MUC5AC expression in A549 and NCI-H292 cells 
MUC5AC is the key mucin found upregulated in patients with COPD (59) and has 
been previously shown to be upregulated by PMA and LPS in airway epithelial cells. 
First the intracellular expression of MUC5AC in A549 and NCI-H292 cells was 
studied using immunofluorescence shown in Figure 3.7. Distinct populations of 
MUC5AC expressing cells were identified, making up around 5-10% of the total cell 
population. In order to investigate the secretion of MUC5AC by the different cell 
types an ELISA was developed. SAEC and 16HBE14o- did not express MUC5AC 
protein basally or upon TNFα treatment (data not shown). Upon studying the 
secretion of MUC5AC in NCI-H292 cell line it was found that 10 ng/mL TNFα did not 
significantly increase MUC5AC secretion (Figure 3.8). However, LPS and PMA 
significantly increased MUC5AC secretion in the NCI-H292 cells (p<0.05 and p<0.001 
respectively) as shown in Figure 3.8, confirming previous research (205, 206). 
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3.4  Discussion 
The novel findings of this study were that IL-6 and IL-8 expression is inducible by 
TNFα and Pseudomonas aeruginosa LPS, and MMP-12 is inducible by TNFα in the 
SAEC.  In addition, IL-6 and IL-8 were inducible by TNFα and LPS in 16HBE14o- cells 
and they also express and secrete MMP-9. Finally, MUC5AC secretion was not 
induced by 10 ng/mL TNFα for 24 hours, but 16 hours of treatment gave a 
significant maximal induction of mRNA in NCI-H292. There was no basal or induced 
MUC5AC mRNA or protein expression in the SAEC or 16HBE14o-.  
This study was novel in the fact that Pseudomonas aeruginosa LPS and TNFα, both 
shown to also be important in COPD, were used as stimuli in the SAEC to look at 
pro-inflammatory mediators which have not been studied before and also to 
compare with 3 different cell lines in order to determine if a cell line model could 
be found to use for future studies. Interestingly, the mediators expressed basally by 
all the cell types were the same except ICAM1 and MUC5AC (Table 3.1 and 3.2). IL-6 
and IL-8 were the key cytokines with basal expression of mRNA and protein in all 
the different cell types tested. 
In exacerbations of COPD the airway epithelium will come under attack from a wide 
range of different pathogens. The airway epithelium has been shown to express 
TLRs in order to detect pathogens and elicit an immune response. Previous studies 
have looked at the effect of LPS on different airway epithelial cells and the 
expression of its recognition receptor TLR4 on the epithelium (207). LPS has 
previously been shown to upregulate the same mediators as cigarette smoke in the 
A549, NCI-H292 and SAEC (198), and therefore is a relevant stimulus. Within the 
literature there appears to be a difference in outcome depending on the type of LPS 
used. Initially, the LPS strain E.coli 0111:B4 was used for this study which did not 
give a significant induction of cytokines in the A549 cells (data not shown). 
However, this strain may not be as potent as others in the airways as it is derived 
from a gut pathogen, with other studies showing it to have little or no effect on 
cytokine and chemokine expression in the A549 and primary SAEC  (201, 208). There is 
evidence that different bacterial strains and also subspecies used at the same 
concentration have different potencies on the induction of IL-8 release in A549 cells 
(14, 209).  This difference is suggested to be from the lipid A structure in the different 
strains (209). 
 93 
One study suggests that Pseudomonas aeruginosa LPS is the most potent stimuli 
and with evidence that this is a common pathogen associated with exacerbation of 
COPD, this stimulus was used (14). It is possible that LPS derived from known lung 
pathogens may be more potent in lung epithelial cells whereas LPS from E.coli and 
Salmonella may be more potent in the gut epithelium where they are a more 
physiologically relevant stimulus, although further investigation is required into this 
hypothesis (207).  
Fewer studies have used Pseudomonas aeruginosa LPS to activate airway epithelial 
cells. In this study the A549 were the most insensitive to Pseudomonas aeruginosa 
LPS treatment and the NCI-H292 were highly responsive. This may be down to 
differences in expression of TLR4 which was not quantified in this study. Previous 
studies have shown that the A549 express TLR1-6 (210), and SAEC have been shown 
to express mRNA for TLR4 (201), and therefore should be able to respond to LPS 
treatment. 
In response to LPS, the maximal induction of IL-1β, IL-6, IL-8 and TNFα was 1 hr in 
both the NCI-H292 and SAEC suggesting the NCI-H292 cells may be a useful model 
for future studies. This 1 hr maximal induction has been shown previously in studies 
on the NCI-H292 cells where the limited production and transient nature of IL-6 and 
IL-8 transcripts was found to be overcome with the addition of cycloheximide 
stabilising transcripts and prolonging induction greater than 1 hr (211-213). 
The 16HBE14o- and A549 cells were more insensitive to LPS treatment in this study 
with little or no significant induction. 1-50 μg/mL of a different variant of LPS have 
previously been shown to increase IL-1β, IL-6, IL-8, TNFα and ICAM1 mRNA and 
protein in the A549 cells at 24 hours (207, 214).  
TNFα is an important pro-inflammatory cytokine that is increased in the sputum 
and systemic circulation of patients with COPD (6, 7). It is one of the most important 
cytokines in COPD pathology and has been shown to drive 70% of cigarette smoke 
induced emphysema in mice (29). Most of its actions are mediated by binding to its 
receptor TNFR1, which is expressed in all human tissues and has been shown to be 
expressed by A549, NCI-H292, and SAEC (215). Although to my knowledge there is no 
literature on TNFR1 expression in 16HBE14o- cells, they did respond to TNFα 
treatment in this study. TNFα is released by alveolar macrophages in response to 
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infection and airway epithelial cell lines have been shown to respond to TNFα and 
also induce TNFα mRNA in response to other stimuli. 
In terms of TNFα treatment, the mRNA induction kinetics of pro-inflammatory 
mediators was more similar between the cell types than with LPS, just with 
different fold inductions. The NCI-H292, 16HBE14o- and SAEC showed the same 
kinetic pattern inducing IL-1β, IL-6, IL-8 and TNFα peaking at 1 hr matching the 
results for LPS treatment. This suggests that the NCI-H292 and 16HBE14o- cells may 
be useful models for future studies. In this case the A549 appeared to be the most 
sensitive to TNFα treatment with the greatest fold induction of cytokine mRNA, 
although induction peaked at 4 hours suggesting different mRNA regulation to the 
other cell types. Of the cytokines tested, IL-6 and IL-8 were the only ones detected 
on TNFα induction (Figure 3.4).  An increase in IL-6 and IL-8 was detected in all the 
cell types and was significant in the NCI-H292 and SAEC. The SAEC had the greatest 
combined expression of IL-6 and IL-8 protein suggesting they may be more sensitive 
to TNFα treatment than the other cell lines. However, the levels of TNFR1 
expression were not tested in the different cell types which may account for the 
difference in cellular sensitivities to TNFα treatment. 
Different concentrations of TNFα have been tested in the A549 cells with 0.1-25 
ng/mL shown to give a dose dependent induction of IL-6, IL-8 and ICAM1 mRNA and 
protein expression with mRNA expression at 1-4 hours matching the findings of this 
study (20, 207, 208, 216-219). TNFα 0.01-10 ng/mL for 24 hours has also been shown to 
dose dependently increase IL8 protein expression in NCI-H292 cells (203, 220). 
The initial step in the inflammatory process in COPD is overexpression of adhesion 
molecules leading to excessive transmigration of neutrophils (221). ICAM-1 is 
elevated in patients with COPD and is crucial in the leukocyte transmigration 
process (66). In this study ICAM1 mRNA was not found to be expressed in the 
16HBE14o- cells. Equally its induction with LPS and TNFα was different in the 
different cell types. ICAM1 mRNA and protein expression has previously been 
shown to be induced by 10 ng/mL TNFα for 6-24 hours in A549 cells which fits with 
the mRNA induction in this study. The signalling pathways involved have been well 
characterised in the A549 cells (204, 222-224). The same concentration has been shown 
to increase soluble ICAM1 expression in NCI-H292 cells (220) and ICAM-1 protein 
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expression has been shown previously in the 16HBE14o- cells although was not 
tested in this study. 
 
TGFβ1 is increased in the small airways of patients with COPD and is important in 
the fibrotic processes (24). TNFα and LPS have been shown to have no effect on 
TGFβ1 protein or bioactive TGFβ1 in A549 cells (225) which matches up with the 
results in this study with neither TNFα or LPS significantly modulating levels of 
TGFβ1 mRNA in any of the cell types tested at the concentrations used. 
 
MMPs are important in repair and remodelling processes within the lung; however, 
an imbalance in protease and anti-protease activity is found in COPD leading to 
alveolar destruction. In patients with emphysema there is an increase in MMP1 and 
MMP9 concentration in BAL and macrophages. MMP12 also plays a predominant 
role in the pathogenesis of chronic lung injury in emphysema as it degrades 
different substrates including elastin which is vital for the elastic recoil of the small 
airways (226). The induction of MMPs -1, -9 and 12 by TNFα was investigated in this 
study. MMP-1 was significantly induced in the two lung cancer cell lines A549 and 
NCI-H292, which is interesting as MMP-1 is involved in tumor invasion (227). 
However, MMP1 is also important for cell detachment and migration which is vital 
during the constant remodelling and repair pathways within the lung, and is 
increased on cellular insult (228). Therefore, the induction in the lung cancer cell 
types may not be for tumour invasion, but for repair processes associated with the 
inflammatory insult in cell lines which have already accumulated genetic damage. 
The expression of MMP-1 mRNA has been shown previously in the SAEC (40) and is 
induced by cigarette smoke, although no effect was seen with TNFα treatment in 
this study and to my knowledge no-one has investigated the effect of TNFα on 
MMP-1 in SAEC previously. It has been shown that there is a region in the promoter 
of MMP-1 in SAEC which is responsive to cigarette smoke and hence gives 
implications for smoking related diseases (229). 
The induction of MMP-9 mRNA expression was similar in all of the cell types tested 
in this study with activation at 8-16 hours of TNFα treatment. This suggests that 
similar signalling pathways may be involved in the induction of MMP-9 mRNA in the 
different cell types although this would need to be confirmed in future studies. 
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MMP-9 enzyme activity was also studied in the SAEC and 16HBE14o- cells. TNFα 
significantly induced MMP9 activity in the SAEC confirming previous studies in 
primary cells (230) (Figure 3.7). The 16HBE14o- expressed much higher basal levels of 
MMP9 activity than the SAEC and there was no significant effect with TNFα 
treatment (Figure 3.7). The induction of MMP-9 by TNFα in the A549 cells was not 
tested in this study as it has already been well characterised (42, 231). 
In the SAEC, MMP-12 mRNA was increased after 8 hours of TNFα treatment, but 
not in any of the other cell lines tested, although MMP-12 protein was not tested. 
The upregulation of MMP12 plays a central role in the transition of emphysema to 
lung cancer which is facilitated by inflammation (232). It is interesting that this only 
occurred in the SAEC. 
 
MUC5AC is a key mucin upregulated in lung disease and is the predominant 
secretion of the airways (59, 233). MUC5AC is known to be expressed by A549 and 
NCI-H292 cells and is inducible in 16HBE14o- cells (234) (235). In this study, the basal 
levels of MUC5AC mRNA and protein was detected in NCI-H292 and A549, but not 
SAEC and 16HBE14o- cells.  
Using immunofluorescence, MUC5AC protein expression was detected in the NCI-
H292 and A549 cells and was found in specific cell populations representing about 
5-10% of the total cells. Previous studies have shown that MUC5AC is exclusively 
expressed in mucous-secreting goblet cells (236), which supports the fact that in the 
SAEC and 16HBE14o- cells no basal or induced MUC5AC was detected as they are 
more homogeneous cell populations without differentiated goblet cells. Although, 
MUC5AC has been shown to be expressed in the small airways (237). TNFα has been 
shown previously to induce mRNA for MUC5AC in A549 cells although this was not 
tested in this study (238). In this study TNFα treatment of NCI-H292 cells for 16 hr 
gave the maximal induction of MUC5AC mRNA expression returning to basal levels 
after 24 hr which fits in with other studies (239). By developing an ELISA, MUC5AC 
secretion was measured in NCI-H292 supernatants (239). Treatment for 24 hr with 10 
ng/mL TNFα did not significantly induce MUC5AC secretion. Previous studies have 
shown a significant induction of MUC5AC secretion in the NCI-H292 cells but at 20 
ng/mL of TNFα (240). 50 ng/mL TNFα has been shown to induce MUC5AC expression 
in cell lysates, not supernatents and hence a measure of intracellular expression not 
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secretion (241). This suggests that either a greater concentration of TNFα or a longer 
treatment time of up to 48 hours is required to give a significant induction of 
MUC5AC secretion. This study showed a significant induction of MUC5AC secretion 
on LPS and PMA treatment which has been shown previously in a time and dose 
dependent manner in the NCI-H292 cells (21, 242), and was used as a positive control 
to confirm the ELISA was working. 
The mechanism of MUC5AC activation is well defined in the literature in the NCI-
H292 cells (205, 206, 238, 243). In particular, MUC5AC protein expression has been shown 
to coincide and be dependent on MMP-9 protein expression, and in this study the 
activation of MUC5AC and MMP-9 mRNA expression was shown to have the same 
kinetics in the NCI-H292 cells (200). In the 16HBE14o- cells, cigarette smoke has been 
shown to induce MUC5AC expression using immunofluorescence, however, as seen 
in this study, there was no detectable basal expression of the protein (235). 
 
The results presented in this chapter are not only important to identify the 
similarities and differences in expression of inflammatory mediators between cell 
lines and primary cells, but are also important to determine which inflammatory 
mediators are expressed and induced and at what time points for further studies 
with vitamin D. Often 2D in vitro culture models are used for research without 
validating in primary cells due to expense and as has been shown in this study and 
others, cell lines can express different inflammatory mediators and respond 
differently to treatment with inflammatory stimuli. For example, this study has 
shown that the kinetics and induction of MMP9 mRNA expression was very similar 
between the different cell types used whereas the expression of MUC5AC and 
MMP1 were different. Therefore, it is important to establish where the similarities 
and differences lie if cell line models are to be used. 
There are limitations to this study. When comparing the mRNA and protein 
expression patterns for the different cell lines, the cell culture media used was not 
the same for each cell line. Instead, specific media was used for each cell line 
according to supplier’s instructions. Different components of cell culture media can 
influence the induction of different inflammatory mediators. Arginine is one 
component which can differ in concentration between culture media types. 
Reduced bioavailability of arginine leads to exaggerated responses enhancing 
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inflammation, which has been shown previously with the production of IL-6 and IL-8 
(244). MEM containing arginine has been shown to give similar response to RPMI-
1640 which were used in this study for the 16HBE14o-, and the NCI-H292 and A549 
cells respectively. It was MEM without arginine, which was not used in the study, 
that gave an exaggerated response (244). However, the SAEC media had many 
supplements and is very expensive so was only used for the SAEC and therefore the 
effect of different culture media components accounting for the differences in the 
expression and induction of inflammatory mediators between the different cell 
types cannot be ruled out. 
Culturing cells in 2D culture as in this study does not completely recapitulate airway 
epithelia biology (245) and thus using 3D air liquid interface culture is important . If 
the cells used in this study were grown at air liquid interface it is possible that they 
would behave differently in terms of induction kinetics and the expression of 
inflammatory mediators. It certainly would make a difference to MUC5AC 
expression in the SAEC and 16HBE14o- cells as at air liquid interface there would be 
a ciliated epithelial surface and differentiation into goblet cells. However, the A549 
and NCI-H292 cell lines are widely characterised and have been used for many years 
since their extraction and hence are likely to have been cultured for so many 
passages in 2D culture that they are too de-differentiated for 3D culture. Equally, 
there is evidence in the literature that airway epithelial cells derived from different 
locations, for example nasal vs bronchial, give different responses (246). This was 
highlighted in this study with the differences in the cellular sensitivities to LPS 
treatment with the A549 being very unresponsive compared to the other cell types 
and this emphasises the importance of validating experiments in primary cells .  
 
Due to the nature of mRNA and the peak induction at 1 hour demonstrated in this 
study, a reduction or increase in mRNA may not have a significant effect on protein. 
Airway epithelial cells in this study only produced protein for IL-6 and IL-8 even 
though the mRNA for a number of pro-inflammatory mediators was detected and 
induced. There are a number of possible reasons for this; high mRNA instability, 
proteins not secreted or secreted before or later than the 24 hour time point used, 
or the methods used are not sensitive enough to detect them.  However, the flow 
cytometric bead array used is highly sensitive and the 24 hour time point for 
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protein detection in supernatents is widely used. mRNA instability has been shown 
previously for transcripts of inflammatory genes so it would not be surprising if cells 
do not secrete proteins for pro-inflammatory mediators as a mechanism of 
controlling acute inflammation to limit local tissue damage. 
Although cigarette smoke is the key inflammatory stimulus related to COPD 
pathology, many studies have looked into the effects of cigarette smoke in SAEC 
and cell lines. LPS has previously been shown to upregulate the same mediators as 
cigarette smoke in the A549, NCI-H292 and SAEC (198) and TNFα is responsible for 
both local and systemic inflammation in COPD, so both are physiologically relevant 
stimulus. 
Although no cell line completely matched the induction kinetics of all mediators 
with the SAEC, the NCI-H292 and 16HBE14o- cells responded similarly in many 
responses and therefore may be useful models to investigate the effects of vitamin 
D in future studies before validating in the SAEC. The A549, although of alveolar 
origin as the SAEC and shown to be a model of ATII in early studies (197), were not a 
good model of the SAEC in this study, as has been suggested in other more recent 
studies (198). 
 
3.5  Conclusion 
IL-6, IL-8, MMP9 and MUC5AC were found to be the key mediators secreted by 
some of the airway epithelial cells used in this study. mRNA for IL-1β, TNFα, TGFβ1, 
MMP-1, MMP-12, and ICAM-1 were also found to be expressed in some cell types. 
This suggests along with other indicators in the literature that airway epithelial cells 
could play an important role in disease pathology by the secretion of pro-
inflammatory mediators that have been shown to be increased in the lungs of 
patients with COPD. There have been no reports comparing the kinetic expression 
patterns of mediators in these three different cell lines to primary small airway 
epithelial cells. The key time point for targeting TNFα/LPS induced cytokine mRNA 
expression was 1 hour in the SAEC, NCI-H292 and 16HBE14o- cells. Although none 
of the cell types completely mirrored the induction kinetics and protein expression 
of every single mediator tested basally and in response to LPS/TNFα, the NCI-H292 
and 16HBE14o- showed similar kinetics to the SAEC in response to TNFα for some 
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inflammatory mediators and therefore could be useful for investigating the effects 
of vitamin D in future studies before validation in the SAEC. 
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Chapter 4:  
Effects of vitamin D on inflammatory 
mediators in airway epithelial cells 
 
 
 
 
 102 
4.1  Introduction 
Vitamin D is a steroid hormone initially recognised for its critical role in maintaining 
calcium and phosphorus homeostasis within the body. However, after the discovery 
of a vitamin D receptor expressed in most tissues there has been an explosion of 
interest in other actions of vitamin D. It is now widely accepted that vitamin D has 
numerous immunomodulatory actions regulating both the innate and adaptive 
arms of the immune response (247). Epidemiological evidence and clinical trials have 
shown vitamin D to be important in lung function with deficiency associated with 
reduced lung function (125). There have also been many associations between 
vitamin D deficiency and the development of COPD, and also with desensitisation of 
lung cancers to vitamin D (164, 248).  
At a cellular level, vitamin D has been shown to modulate the response of cells 
derived from the airways to respiratory syncytial virus infection and also to LPS 
treatment (150, 249). In addition, vitamin D has been shown to modulate a wide range 
of different cellular signalling pathways including p38 MAPK (116), PI3K (117), JNK (118), 
ERK (119), NFkB (112) and Rho Kinase (120). 
 
The airway epithelium is an important barrier to the external environment and 
being the first point of contact for noxious substances and pathogens it plays a 
crucial role in the initiation of the inflammatory response. Airway epithelial cells 
have been shown to constitutively activate vitamin D. This is the first study to look 
at the effects of 1,25(OH)2D3 in airway epithelial cells on mediators important in 
COPD pathology. In this study the effect of vitamin D in primary human small airway 
epithelial cells and cell lines was studied in order to determine how vitamin D may 
be beneficial in modulating inflammatory mediators important in COPD and lung 
cancer pathology. Leading on from the characterisation of the inflammatory 
mediators expressed by widely used airway epithelial cell lines and primary cells, 
the sensitivity of cell lines to vitamin D treatment was studied along with its ability 
to modulate key mediators of lung inflammation including IL-1β, IL-6, IL-8, TNFα, 
MMP9 and MUC5AC. 
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4.2  Aims of this study  
 To determine the sensitivity of primary human small airway epithelial cells 
and widely used human airway epithelial cell lines to vitamin D treatment 
 To investigate the effects of vitamin D on the basal expression of 
inflammatory mediators in the human airway epithelial cells 
 To investigate the effects of vitamin D on the induction of inflammatory 
mediators by TNFα/LPS in human airway epithelial cells 
 To investigate the mechanism of action of vitamin D in human airway 
epithelial cells 
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4.3  Results 
Part One – Effects of vitamin D on the basal expression of 
inflammatory mediators in human airway epithelial cells 
4.3.1  Effects of vitamin D treatment on cell proliferation in lung cancer cell lines 
A549 and NCI-H292 
Few studies have investigated the effects of vitamin D or its analogs in airway 
epithelial cells. Previous studies have shown anti-proliferative effects of 
1,25(OH)2D3 in different lung cancer cell lines 
(165-167). Therefore, the first objective 
in this study was to determine if any anti-proliferative effects are seen in the lung 
cancer cell lines used for this study. A549 and NCI-H292 cells were treated with 10 
or 100 nM 1,25(OH)2D3 for 72 hours and cell proliferation was measured using an 
MTS assay. 1,25(OH)2D3 treatment had no significant effect on proliferation of 
either A549 or NCI-H292 cells (Figure 4.1).  
 
4.3.2 Sensitivity of airway epithelial cells studied to vitamin D treatment 
It was next important to establish whether or not all of the cell types used were 
responsive to vitamin D treatment and expressed the means with which to use 
vitamin D. The enzyme CYP24 is a key metabolising enzyme of vitamin D and as 
levels of vitamin D are tightly regulated, addition of vitamin D induces the 
expression of CYP24 as a gene containing a vitamin D response element regulated 
by receptor-ligand binding (250). The different cell types were treated with 
1,25(OH)2D3 and the induction of CYP24 mRNA expression was measured using qRT-
PCR. Primary small airway epithelial cells, with a significant induction of mRNA after 
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24-48 hours (p<0.05), showed the highest sensitivity to 1,25(OH)2D3 treatment 
followed by NCI-H292 24-48 hours (p<0.01) and 16HBE14o- cells 24 hours (p<0.05) 
and 48 hours (p<0.01) shown in Figure 4.2. 
1,25(OH)2D3 had no effect on CYP24 expression in A549 cells (Figure 4.2) suggesting 
that they were not sensitive to 1,25(OH)2D3 treatment. The basal expression of 
CYP24 mRNA was also measured and compared among the different cell types 
(Figure 4.2). A549 were found to express high basal amounts of CYP24 mRNA, 
which was significantly different to the other cell types tested in the study 
(p<0.001), suggesting that 1,25(OH)2D3 may be metabolised before it has an 
opportunity to act in these cells. 
VDR mRNA expression was also studied to note any differences between the cell 
lines. The expression of VDR mRNA was highest in the primary cells, although there 
was no significant difference between the basal expression of VDR in the different 
cell types (Figure 4.2). 1,25(OH)2D3 significantly induced VDR mRNA expression in 
the NCI-H292 at 16 hr (p<0.05); however, this was not significant in SAEC and 
16HBE14o- cells. Interestingly, VDR expression was significantly increased at 16 
(p<0.05) and 24 hours (p<0.01) following 1,25(OH)2D3 treatment in A549 cells, 
which may be a mechanism where the cell upregulates receptor expression to make 
use of any vitamin D that has not been metabolised.  
Cancer cells have been shown to dysregulate the vitamin D pathway in order to 
avoid the anti-cancer and anti-proliferative effects of vitamin D treatment. The 
CYP24:VDR ratio has been identified as important with some cancers increasing 
CYP24 expression and decreasing VDR expression to dampen down vitamin D 
signalling. As such in this study the SAEC had the highest VDR expression and lowest 
CYP24 expression with the greatest induction of CYP24 on vitamin D treatment. This 
suggests that they are the most responsive cell type to vitamin D whereas 
conversely the A549 cells had the greatest basal CYP24 expression and lowest VDR 
expression suggesting they are the least responsive cell line to vitamin D treatment 
of those that were used in this study. 
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4.3.3 Effects of vitamin D on basal expression of IL-6 and IL-8 in cells responsive to 
vitamin D treatment 
In chapter 3, IL-6 and IL-8 were the key cytokines tested that were detectable at 
both mRNA and protein levels in the different airway epithelial cells tested. It was 
firstly investigated if 1,25(OH)2D3 had any effect on these mediators in the cell 
types studied except for in the A549 cells which appear to be the least responsive 
to vitamin D. 
In SAEC and 16HBE14o-, IL-6 mRNA expression was significantly reduced upon 
treatment with 1,25(OH)2D3, (p<0.001) and (p<0.01) respectively for each time 
point tested shown in Figure 4.3A. IL-8 mRNA was significantly increased at 16 
hours in the NCI-H292 (p<0.01) Figure 4.3B. There was no significant difference in 
protein expression between the different cells on vitamin D treatment however, 
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there was a trend of a decrease in IL-6 in SAEC and both IL-6 and IL-8 in the 
16HBE14o- , but an increase in IL-8 in the SAEC (Figure 4.3C and D). 
 
 
4.3.4 Mechanism of vitamin D modulating basal IL-6 mRNA expression 
The reduction of basal IL-6 mRNA and protein expression by 1,25(OH)2D3 was 
mirrored in the SAEC by the 16HBE14o- and so the mechanism of action was 
investigated in the 16HBE14o- cells. 1,25(OH)2D3 has previously been reported to 
modulate NFκB (36, 90, 108-113, 115), p38 MAPK (116), PI3K (117), JNK (118), ERK (119) and Rho 
kinase (120-122) signalling pathways. 
A range of inhibitors of these pathways were used to determine if intracellular 
kinases were involved in the regulation of IL-6 by 1,25(OH)2D3. Firstly, the 
cytotoxicity of the different signalling pathway inhibitors was tested using a cellular 
cytotoxicity assay in order to determine a non cytotoxic concentration to use within 
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the cells (Appendix Figure 7.1). Concentrations of 1-10 μM of each inhibitor was not 
found to be toxic except with the proteasomal inhibitor MG132 which was 
significantly cytotoxic at 5 (p<0.01) and 10 μM (p<0.001) (Appendix Figure 7.1). 
Therefore the maximum tolerated dose of 10 μM was used for each inhibitor 
except MG132 where 1 μM was used. 
 
Treatment of 16HBE14o- cells with 100 nM 1,25(OH)2D3 for 24 hours reduced basal 
IL-6 expression as shown in Figure 4.4 A-E. Treatment of 16HBE14o- with 10 μM 
SB203580, PD98058 or LY294002, p38 MAPK, MAPKK and PI3K inhibitors 
respectively, had no significant effect alone or in combination with 1,25(OH)2D3 on 
basal IL-6 mRNA expression although data was variable. 
 
Using 10 μM Y-27632 dihydrochloride, a selective inhibitor of the Rho-associated 
protein kinase (ROCK) p160, had no significant effect on basal IL6 mRNA expression 
although this was variable. Combined treatment of inhibitor with 1,25(OH)2D3 
significantly reduced IL6 mRNA expression the same as 1,25(OH)2D3 alone (p<0.05) 
when compared to basal levels, but not to the inhibitor alone. This suggests 
1,25(OH)2D3 does not regulate ROCK to reduce IL6 expression. 
 
MG132 is a 26S proteasome inhibitor, which also inhibits NFκB activity by  
preventing degradation of its inhibitor, IκB. MG132 increased basal IL-6 mRNA 
expression and also increased its expression when combined with 1,25(OH)2D3 
although the data was variable and not significant so no conclusions can be drawn. 
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4.3.5 Effects of vitamin D on basal expression of mRNA for other inflammatory 
mediators 
As no conclusive mechanism of action could be determined for the effect of 
1,25(OH)2D3 in airway epithelial cells, the effects of 1,25(OH)2D3 on basal expression 
for other cytokine mRNA which had been shown to be expressed in airway 
epithelial cells was tested. This allowed comparison of the effects of 1,25(OH)2D3 on 
different mediators which may point to certain transcription factors or shared 
signalling intermediates that are modulated by 1,25(OH)2D3. 
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1,25(OH)2D3 had no significant effect on IL1β or TGFβ1 mRNA basal expression in 
any cell type and significantly induced TNFα mRNA after 24 hours of treatment in 
the NCI-H292 cells (p<0.05) Figure 4.5. 1,25(OH)2D3 significantly reduced the 
expression of MMP9 in the SAEC after 24 hours (p<0.05) but not in the other cell 
lines. IL-10 and IL-12p70 basal mRNA expression was not detected basally (see 
section 3.3.2, chapter 3) however, they have been shown previously to contain 
vitamin D response elements and therefore the effects of 1,25(OH)2D3 on the 
expression of these was investigated, but still no mRNA was detected (data not 
shown). 
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4.3.6 Effects of vitamin D on MMP9 enzyme activity in airway epithelial cells 
As 1,25(OH)2D3 significantly reduced MMP9 mRNA in the SAEC, the effects on 
enzyme activity were investigated. SAEC and 16HBE14o- cells were treated with 100 
nM 1,25(OH)2D3 for 24 hours and the cell supernatents were collected and analysed 
using gelatin zymography to measure MMP9 enzyme activity. Interestingly, there 
was no significant difference on 1,25(OH)2D3 treatment in the 16HBE14o- cells 
fitting with the mRNA data, however, paradoxically there was an increase in MMP9 
enzyme activity in the SAEC after 1,25(OH)2D3 treatment although this was not 
significant. Representative gelatin zymography images are shown in Figure 4.6A 
with the densitometry values of a triplicate experiment shown in Figure 4.6B.  
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4.3.7 Mechanism of action of vitamin D on induction of TNFα mRNA in NCI-H292 
cells As shown previously in Section 4.3.5 and Figure 4.5, 1,25(OH)2D3 significantly 
activates TNFα mRNA expression after 24 hour of treatment in the NCI-H292 cell 
line. In order to determine a possible mechanism of action, molecular inhibitors of 
p38 MAPK, ERK MAPK, PI3K, ROCK, JNK and NFκB were used to try and block this 
effect. Firstly, the cytotoxicity of the different inhibitors in the NCI-H292 cells was 
studied to ensure the concentrations used were not cytotoxic (Appendix Figure 
7.2).  
 
SB203580 a p38 MAPK inhibitor, LY294002 a PI3K inhibitor and SP600125 a JNK 
inhibitor, had no significant effect alone but in combination with 1,25(OH)2D3 gave 
a synergistic induction of TNFα (p<0.05 at least) (Figure 4.7 A,C,F) suggesting that 
these signalling molecules are negative regulators of TNFα mRNA expression. Using 
a ROCK inhibitor Y-27632 dihydrochloride, PD98059 MAPKK inhibitor and MG132 
proteasomal inhibitor the data was more variable (Figure 4.7 B,D,E) and hence was 
not significantly different so no conclusions can be drawn and further study is 
required. 
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4.3.8 Effect of vitamin D on the basal expression of MUC5AC in the different cell 
types 
MUC5AC was found to be expressed in the NCI-H292 cell line used in this study 
which was responsive to 1,25(OH)2D3 treatment. The effect of 1,25(OH)2D3 on basal 
MUC5AC mRNA expression and MUC5AC protein secretion was determined. 
1,25(OH)2D3 significantly reduced basal MUC5AC mRNA expression after 24 hours 
of treatment (p<0.01) and significantly reduced basal MUC5AC protein secretion 
after 24 hours of treatment (p<0.001).  
 
 
Part Two – Effects of vitamin D on inflammatory responses induced by 
TNFα or LPS 
4.3.9 Effects of vitamin D on TNFα induction of inflammatory mediators 
In chapter 3, the induction of inflammatory mediators by TNFα and LPS was 
investigated and it was concluded that 1 hr of treatment gave peak induction of 
mRNA expression for the various pro-inflammatory mediators. Therefore, cells 
were incubated with 1,25(OH)2D3 for various times and concentrations before the 
addition of TNFα for 1 hr in the different airway epithelial cells.  
In SAEC, pre-incubation with 100 nM 1,25(OH)2D3 was found to significantly reduce 
TNFα induced IL-6 mRNA and protein expression at both 1 and 24 hr incubation 
(p<0.05 at least)(Figure 4.9A and C). A similar effect was found in the 16HBE14o- for 
IL-6 protein expression (Figure 4.9C). 1,25(OH)2D3 did not significantly affect TNFα 
induced IL-8 mRNA and protein expression in the SAEC or 16HBE14o- cells. 
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The NCI-H292 cells were also found to have a non significant reduction of IL-6 and 
IL-8 mRNA with 1 hr pre-incubation, but a significant induction of IL-6 and IL-8 
mRNA after 24 hr pre-incubation of 1,25(OH)2D3 before TNFα treatment (p<0.05 at 
least) with a non significant trend of increased IL-6 and a significant increase in IL-8 
protein expression (p<0.01) with 24 hr of 1,25(OH)2D3 pre-treatment (Figure 4.9A-
D). 
 
 
4.3.10 Dose dependent effects of vitamin D in SAEC and NCI-H292 
The effects in 4.9 were using the highest dose of 1,25(OH)2D3 100 nM. Different 
doses were used in order to determine whether or not this was a dose dependent 
effect. Indeed, using 1-100 nM 1,25(OH)2D3 pre-treatment for 1 or 24 hr in the SAEC 
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leads to a dose dependent reduction in IL-6 mRNA expression. In addition, the non 
significant reduction in IL-6 expression with 1 hour pre-treatment in the NCI-H292 
as well as the significant induction with 24 hour pre-treatment (p<0.001) were also 
found to be dose dependent (Figure 4.10). 
 
 
4.3.11 Vitamin D does not affect TNFα induced IL-6 and IL-8 mRNA expression in 
the CYP24 over-expressing A549 cells 
Although A549 cells express high quantities of CYP24, it was investigated whether 
or not treatment with 1,25(OH)2D3 in this cell line would have any effect on TNFα 
induced IL-6/IL-8 expression. 1,25(OH)2D3 (1-100 nM) for either 1 hr or 24 hr before 
1 hr TNFα had no significant effect on IL-6 and IL-8 mRNA expression in the A549, 
again suggesting that the cells are insensitive to 1,25(OH)2D3 treatment (Figure 
4.11). 
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4.3.12 Effects of vitamin D on LPS induced IL-6 and IL-8 mRNA expression  
To determine whether the effects of vitamin D on induced expression of cytokines 
is unique for the TNFα signalling or whether a similar effect would be seen using 
other inflammatory stimuli, LPS was used and investigated in the SAEC and NCI-
H292 cells. Again, pre-treatment of SAEC for 1 or 24 hrs with 100 nM 1,25(OH)2D3 
before LPS treatment for 1 hr significantly reduced IL-6 mRNA expression but had 
no effect on IL-8 mRNA expression. Similarly, 1 hr pre-treatment of NCI-H292 
before LPS treatment gives a significant reduction in IL-6 and IL-8 mRNA expression 
(p<0.001 and p<0.05 respectively) and 24 hr pre-treatment gives a significant 
induction of both IL-6 and IL-8 mRNA expression (p<0.001). 
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4.3.13 Effects of vitamin D on TNFα/LPS induction of mRNA for other 
inflammatory mediators in NCI-H292 cells 
In order to determine whether the biphasic effect found in the NCI-H292 cells were 
only found with IL-6 and IL-8, the effects of 1,25(OH)2D3 pre-treatment on LPS and 
TNFα induction of IL1β and TNFα was also studied. Indeed, the same pattern was 
found with a significant induction with 24 hr pre-treatment (Figure 4.13). 
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4.3.14 Effects of vitamin D pre-treatment on MMP9 mRNA expression and enzyme 
activity  
In section 4.3.6, 1,25(OH)2D3 treatment was found to reduce basal MMP9 mRNA 
expression in SAEC and 16HB14o- but paradoxically increased MMP9 enzyme 
activity in the SAEC. In this section the effect of 1,25(OH)2D3 on TNFα induction of 
MMP9 mRNA and enzyme activity was investigated. Pre-treatment for 1 or 24 
hours with 100 nM 1,25(OH)2D3 significantly reduced TNFα induction of MMP9 
mRNA expression in the SAEC and the 16HBE14o- cells (Figure 4.14A). This effect 
was mirrored for enzyme activity in the 16HBE14o- cells with a significant reduction 
of expression on 24 hours pre-treatment with 1,25(OH)2D3 (Figure 4.14B and C), 
although as shown in Figure 3.6 TNFα did not significantly induce MMP9 enzyme 
activity in the 16HBE14o- cells. Similar to the basal expression in section 4.4.6, 
paradoxically there was a synergistic induction of MMP9 enzyme activity in the 
SAEC on 24 hrs 1,25(OH)2D3 pre-treatment before TNFα addition (Figure 4.14B and 
C). 
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4.3.15  Effects of vitamin D pre-treatment on MUC5AC induction by known 
inducers  
Pre-treatment of the NCI-H292 mucous expressing cell line for 24 hours with 
1,25(OH)2D3 gave a significant reduction in TNFα induced MUC5AC mRNA 
expression (p<0.05) (Figure 4.15A).  
In chapter 3 section 3.3.8, LPS and PMA were found to significantly induce MUC5AC 
protein secretion. Pre-treatment with 1,25(OH)2D3 for 24 hours before stimulation 
with these compounds for 24 hours was found to significant reduce the induction of 
MUC5AC protein secretion, even for TNFα which did not significantly induce 
expression in section 4.4.8 (p<0.01 at least) (Figure 4.15B).  
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4.4  Discussion 
The novel findings in this study were that vitamin D modulates IL-6 expression in 
the SAEC, 16HBE14o- and NCI-H292 cells. In addition, vitamin D exhibited a biphasic 
response in the NCI-H292 cells with a reduction or induction of cytokine mRNA 
depending on the length of pre-incubation. In the mucous producing NCI-H292 
cells, vitamin D was also shown to block MUC5AC basal mRNA expression and 
protein secretion and its induction by known activators. These findings help to 
further characterise the potential benefits of vitamin D in inflammatory lung 
diseases such as chronic obstructive pulmonary disease and lung cancer. The 
mechanism of action of vitamin D was also studied, but the results were 
inconclusive and this area requires further investigation in the future. 
There are very few studies where vitamin D or its analogs have been used in airway 
epithelial cells. This is the first study to report the effects of vitamin D in primary 
small airway epithelial cells. A number of studies have shown an anti-proliferative 
effect of vitamin D treatment in some lung cancer cell lines expressing the VDR. 
1,25(OH)2D3 and analogs significantly inhibited cell proliferation in the NCI-H82 and 
NCI-H209 small cell lung carcinoma and the EBC-1 and H520 non-small cell  
carcinoma cell lines (165-167). However, in the NCI-H292 and A549 lung cancer cells 
used in this study, vitamin D was not found to have an anti-proliferative effect 
(Figure 4.1) despite the NCI-H292 cells being responsive to 1,25(OH)2D3 treatment.  
A recent study has found that vitamin D does have an antiproliferative effect in 
both the A549 and NCI-H292 cells but this after 7 days of treatment (251). Inhibiting 
CYP24 increased this antiproliferative effect.  
Previous studies have shown that cancer cells, including those derived from lung 
tissue, can harbour mutations/alterations dysregulating parts of the vitamin D 
pathway, by altering expression of the VDR, CYP27 and CYP24. This is thought to be 
a mechanism by which tumours can evade the anti-cancer properties of vitamin D. 
In this study, the expression of CYP24 and VDR was compared in all the cell types 
used to see if they are responsive to vitamin D treatment. All of the cells tested in 
this study expressed detectable basal levels of CYP24 and VDR mRNA. CYP24 was 
increased upon treatment with vitamin D in all cells except A549 suggesting they 
are insensitive to vitamin D treatment, which has previously been shown (179). SAEC 
had the lowest expression of basal CYP24 mRNA and the greatest VDR mRNA 
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expression. They also had the greatest sensitivity to vitamin D treatment with the 
largest fold induction of CYP24 on vitamin D treatment. 16HBE14o- cells were also 
sensitive to vitamin D with an induction of CYP24 on vitamin D treatment which 
also is novel. This is the first study to my knowledge to show that primary small 
airway epithelial cells are sensitive to vitamin D treatment. Previous studies have 
shown a high expression of CYP24 by the A549 cells, and a relatively high 
expression in the NCI-H292 and expression of VDR by both cell types which was also 
found in this study (123, 179). CYP24 upregulation and VDR down regulation has been 
shown previously in lung tumours and lung cancer cells in comparison to normal 
tissue, with 1,25(OH)2D3  clearance being enhanced in malignant cells through 
transcriptional regulation of CYP24 and metabolism of CYP24 mRNA (106, 179, 180, 252, 
253). Although the A549 cells were not found to be sensitive to vitamin D treatment 
in this study, a recent study has shown that treatment of A549 cells with 
1,25(OH)2D3 decreases DNA damage 
(254). 
 
IL-6 and IL-8 were the key cytokines of those tested that were detectable at both 
protein and mRNA levels in the different airway epithelial cells. Interestingly, in this 
study 1,25(OH)2D3 was shown to reduce basal expression of IL-6 mRNA in the SAEC 
and 16HBE14o- and appeared to increase IL-8 mRNA expression in the SAEC, with 
no significant effects in the NCI-H292. A previous study on the effect of 1,25(OH)2D3  
on IL-6 and IL-8 expression in cells from cystic fibrosis showed modulation of both 
of these mediators (150). To further investigate the reduction in IL-6 mRNA which 
was mirrored by the 16HBE14o- in the SAEC, the 16HBE14o- were used to study the 
potential signalling pathways involved. 
Previous studies have shown that vitamin D reduces IL-6 production in normal 
prostate cells by inhibition of p38 (116) and that induction of IL-6 by inflammatory 
mediators is regulated by p38 (255). p38 is important in regulating the biosynthesis of 
pro-inflammatory cytokines namely IL1β, TNFα, IL-6 and IL-8 and therefore is a 
major contributor to inflammation and may play a critical role in the inflamed lung 
(256). It has also been shown to be important in increasing IL-6 synthesis in airway 
epithelial cells (257). 
The reduction in IL-6 mRNA expression after treatment with 1,25(OH)2D3 was 
similar to the effect of p38 MAPK and PI3K inhibition, and also similar to that of the 
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combined treatment of 1,25(OH)2D3 and either the p38 MAPK or PI3K inhibitor, but 
these were not significantly different from the basal expression and so no 
conclusions can be made. Further repetition of this data is required. 
 
Vitamin D has also been shown to modulate the RhoA/Rho Kinase ROCK pathway in 
different cell types (121, 122). In this study, inhibition of ROCK was not found to have 
any effect on IL-6 expression and did not affect the reduction of IL-6 expression by 
vitamin D suggesting that this pathway is not the mechanism of action. 
 
A key transcription factor which has been shown in many previous studies to be 
modulated by vitamin D is NFκB. In this study, using a proteasome inhibitor MG132 
to inhibit activation of NFκB lead to an increase in basal IL-6 expression but this was 
not significant and the data were variable and inconclusive. Vitamin D has been 
shown to modulate NFκB DNA binding activity by increasing IκBα by a number of 
mechanisms – increasing mRNA stability, decreasing phosphorylation, reducing 
nuclear NFκB translocation, increasing mRNA transcription, protein translation, 
post-translational modifications and degradation by the proteasome (110, 111, 249, 258). 
From this there is a suggestion that vitamin D would likely be modulating NFκB. 
However, further studies are required to fully determine how vitamin D is 
modulating these responses in airway epithelial cells. 
NFκB is the key transcription factor controlling the expression of many 
inflammatory mediators and therefore you might expect that if vitamin D was only 
modulating this signalling pathway, that it would modulate all the mediators in the 
same way. In order to determine if the effects of vitamin D were common to 
specific molecular pathways which were unable to be defined using the inhibitors, 
the effects of vitamin D on the mRNA expression of other inflammatory mediators 
were studied. 1,25(OH)2D3 treatment significantly reduced the expression of MMP9 
mRNA expression in the SAEC and significantly induced the expression of TNFα 
mRNA in the NCI-H292 cell lines. It appears that the effects of vitamin D vary in 
different cell lines and for different mediators making defining the mechanism of 
action more complex. However, because these mediators are all regulated by NFkB 
and yet vitamin D is having different effects it suggests that if vitamin D is 
modulating NFkB it is doing it by different mechanisms to give a different effect, or 
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that it is not the only pathway that vitamin D is modulating and therefore giving 
different effects. 
IL-10 and IL-12p70 mRNA basal expression was not detected previously in basal 
airway epithelial cells however, being primary vitamin D target genes under direct 
transcriptional control of the VDR (106), the expression  of these was investigated on 
vitamin D treatment, but still no mRNA was detected in the cell types tested. 
Interestingly, vitamin D treatment in the NCI-H292 cells was found to increase TNFα 
after 24 hours of treatment. In order to determine a possible mechanism of action 
molecular inhibitors were used to try and block this effect. Vitamin D has been 
shown to increase TNFα mRNA expression after 24 hours of treatment in prostate 
cancer cells. However, only mRNA was increased as additional cofactors were 
required for protein expression (259). 
Inhibiting p38 MAPK, PI3K and JNK  had no significant effect alone on the induction 
of TNFα basal mRNA in the NCI-H292 cells but with 1,25(OH)2D3 gave a synergistic 
induction of TNFα suggesting that these pathways are involved in negatively 
regulating basal TNFα mRNA expression in these cells. p38 MAPK has been shown 
to be key in regulating mRNA stability so it may be that p38 MAPK reduces TNFα 
stability and inhibiting it leads to an increase in TNFα mRNA but further 
investigation into this would be required. Using MAPKK and proteasome inhibitors 
the data was more variable and hence was not significantly different which could 
mean that vitamin D does not modulate any of these pathways to increase TNFα 
but further confirmation is required. 
It has already been shown that in CFBE41o− and CFTE29o− cystic fibrosis cells 
vitamin D has an immunomodulatory action on the induction of IL-6 and IL-8 (150) 
and it was hypothesised in this study that vitamin D would have the same effect in 
other airway epithelial cells. Vitamin D was found to significantly reduce TNFα 
induced IL-6 mRNA and protein expression in the SAEC at both 1 and 24 hour 
preincubation time points, and IL-6 protein in the 16HBE14o-.  Interestingly, there 
was no significant effect of vitamin D on IL-8 protein, but there was a reduction in 
IL-8 mRNA in the 16HBE14o- and an induction at 24 hours pre-incubation in the 
NCI-H292 cells. 
The reduction of IL-6 mRNA induced by TNFα in the SAEC was dose dependent 
although this effect could be down to 1,25(OH)2D3 reducing basal IL-6 mRNA 
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expression rather than blocking TNFα signalling (Figure 4.3, 4.10). In addition the 
biphasic reduction and induction of IL-6 mRNA at the 1 and 24 hour pre-incubations 
respectively was a dose dependent effect in the NCI-H292 cells (Figure 4.10). 
The effect of vitamin D on these mediators in the insensitive A549 cells was also 
studied and found that there was no effect whatever dose or time point suggesting 
that CYP24 is preventing the action of vitamin D in this cell line (Figure 4.11). 
However, in order to prove this further studies would be required to block CYP24 
and see if this allows a similar effect of vitamin D in these cells as the SAEC or 
whether there are other factors at play in this cancer cell lines. 
These different modulating effects of 1,25(OH)2D3 in the SAEC and NCI-H292 cells 
were also found when using LPS as the inducer of inflammatory cytokines (Figure 
4.12).  In cystic fibrosis cells, agonists of the VDR were found to inhibit IL-6 and IL-8 
protein expression when used 1 hour before exposure to LPS (150). This fits in with 
the 1 hour incubation data for SAEC and NCI-H292 cells with IL-6 but not IL-8 
expression. 
Studies have also shown that vitamin D can reduce cytokine production induced by 
LPS in a number of different cell types and one of the mechanisms is by reducing 
TLR4 expression (260). This also fits in with in vivo data from a hamster model of 
acute lung injury (ALI) whereby ALI was induced by lipopolysaccharide (E.coli 
0111:B4)  inhalation, and vitamin D inhibited neutrophil recruitment in the lung by 
40% (261). 
It is key that studies using vitamin D in other cell types have shown reduction of IL-8 
expression as well as IL-6 by vitamin D whereas here we show just modulation of IL-
6 suggesting different regulation.  
Another novel finding of this study was the biphasic response of vitamin D in NCI-
H292 cells. There has been a similar finding in the literature looking at the effect of 
1,25(OH)2D3 on basal expression of cytokines in HL-60 leukaemic cells showing a 
reduction of mRNA expression at 4 hours and increase at 24 hours for a range of 
inflammatory mediators. This was found to be due to suppression and then 
reactivation of NFκB. The suppression was associated with increased IκBα and the 
late reactivation was associated with vitamin D stimulated phosphorylation of IκBα 
requiring active AKT and IKK pathways (112). A biphasic effect has also been found in 
U937 leukaemic cells where pre-treatment for 3-6 hours with vitamin D before LPS 
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gave a reduction in TNFα mRNA whereas pretreatment for 12-48 hours gave an 
induction of TNFα mRNA (107). From this study it is clear that the biphasic response is 
cell type specific and it may be an important factor in cancer development.  
MMP9 is a key protease upregulated in COPD responsible for destructive processes 
within the lung. In this study 1,25(OH)2D3 was found to reduce MMP9 mRNA 
expression in the SAEC but paradoxically there was an increase in MMP9 enzyme 
activity. Equally, pretreatment with vitamin D significantly reduced TNFα induced 
MMP9 mRNA expression in the SAEC, but synergistically induced MMP9 enzyme 
activity. Vitamin D has been shown to reduce MMP9 expression in vitro in human 
airway smooth muscle cells (151) and in vivo in patients with pulmonary tuberculosis 
(141, 173). 
Although the mechanism of action for this was not studied, vitamin D has been 
shown to attenuate TNFα induction of MMP9 expression in keratinocytes  by 
inhibiting JNK and NFκB pathways (118). One hypothesis to test in the future that 
relates to this is the newly defined vitamin D receptor ERp60 which has been found 
to be present on extracellular matrix vesicles in chondrocytes and causes release of 
MMPs on vitamin D treatment. Therefore this fits in with the data in the SAEC 
where MMP9 mRNA was reduced but enzyme activity was increased possibly 
because MMP9 was stored up and vitamin D treatment caused it to be released 
from intracellular/extracellular vesicles into the supernatant (262). 
MMP-9 has also been shown to be crucial in secretion of MUC5AC on LPS treatment 
(21). In the mucous producing NCI-H292 cell lines vitamin D treatment was found to 
reduce basal MUC5AC mRNA and protein expression. Being at both mRNA and 
protein levels suggests that vitamin D is acting at the transcription factor level or 
reducing the stability of transcripts in order to reduce expression. Vitamin D pre-
treatment also blocked the induction of MUC5AC secretion by LPS and PMA. The 
mechanism of this needs further investigation. The EGFR pathway is key in MUC5AC 
secretion in this cell type and vitamin D has been shown to modulate this pathway 
previously in different cancer cell types but further investigation would be required  
to determine if it is a mechanism in this cell type (21). It has also been shown that 
MUC5AC secretion is inhibited by antagonists of RARα, and although vitamin D was 
not tested it is an antagonist of this pathway suggesting that it could be a 
mechanism of action (263).  
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A limitation to the study is that as yet no-one has shown how much active vitamin D 
can be produced within the lung given sufficient circulating levels of 25(OH)D3. A 
range of doses 1-100 nM were tested and a number of effects were shown to be 
dose dependent giving strength to the evidence, but to reach a statistically 
significant effect required 100 nM vitamin D. Previous studies have shown the 
capabilities of airway epithelial cells to convert 25(OH)D to 1,25(OH)2D and 
therefore in this study 1,25(OH)2D was used. It is possible that much higher local 
transient concentrations of 1,25(OH)2D3 could be produced in airway epithelial cells 
but that has yet to be shown. It is possible that the concentration of 1,25(OH)2D3 
used in this study is not physiological. However, the main concept of this study was 
to determine the effects of vitamin D and there is a therapeutic potential to 
administer high dose vitamin D in an inhaled form directly to the lung epithelium, 
and doses used in this study could be pharmacological. 
The protein expression for different mediators was not measured in every study 
done and mechanistically only the mRNA was studied. Some of the mechanistic 
data was more variable and inconclusive and needs further investigation with 
increasing repetitions and protein data to show by western blotting either changes 
in the levels of different signalling components, or differences in their 
phosphorylation status to determine what vitamin D is activating/inactivating. 
 
This study has shown that the A549 cells appear insensitive to vitamin D treatment 
and this is likely to be due to high expression of CYP24 which has been shown 
before, but to prove the difference between the cells is due to CYP24 expression, 
further studies would have to knock out CYP24 and see if vitamin D has the same 
effect as in the other cell types or vice versa. Another limitation is that this study 
did not determine the protein expression of CYP24 and VDR. Studies have shown 
that CYP24 mRNA and protein levels correlate however, the expression of VDR 
mRNA and protein can be completely independent. 
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4.5  Conclusions 
This study has shown that vitamin D modulates the basal expression and induction 
of IL-6 in different airway epithelial cells but interestingly not IL-8. Vitamin D was 
also found to modulate MMP9 enzyme activity and reduce the secretion of 
MUC5AC. Vitamin D has shown some attributes which overall may be beneficial in 
lung diseases.  Although the expression of inflammatory mediators were very 
similar between the different airway epithelial cells tested, their response to 
vitamin D treatment were more different. This could be down to individual 
variability, or there may be distinct cellular subtypes which can define how vitamin 
D modulates expression of inflammatory mediators. Further studies are required to 
further characterise the effects of vitamin D and its mechanism of action which will 
be crucial to fully determine the benefits of vitamin D. 
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Chapter Five: 
Effects of vitamin D on oxidative stress in 
airway epithelial cells 
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5.1  Introduction 
COPD is characterised by excessive inflammatory responses enhanced by the 
generation of oxygen and nitrogen free radicals induced by factors such as cigarette 
smoke (199). Oxidative stress and the generation of ROS is a key process in cellular 
respiration. However, in excess it also drives inflammation and is very important in 
the pathology of COPD and lung cancer. Patients with COPD show evidence of 
oxidative stress in their lung tissue (199). This is predominantly due to the large 
number of carcinogenic chemicals which induce free radicals and oxidative stress 
within the lung tissue during smoking. However, exposure to pathogens and also 
other inflammatory agents can also induce oxidative stress and dysregulate the 
anti-oxidant/pro-oxidant balance. The main ROS produced are the superoxide anion 
(O2-), hydrogen peroxide (H2O2) and the hydroxyl radical (OH-). A common feature 
of inflammatory lung disease is the infiltration of inflammatory cells which when 
activated, generate O2- which is converted to H2O2 by superoxide dismutase 
(264).  
Vitamin D has been shown to be key to innate immune responses by inducing ROS 
production in alveolar macrophages in order to fight infections (114, 265).  It has also 
been shown to have both anti-oxidant and pro-oxidant properties in different cell 
types (266-268). However, it has yet to been seen whether vitamin D has any anti or 
pro-oxidant effects in the airway epithelium.  
 
In order to determine the effect of vitamin D on oxidative stress in airway epithelial 
cells, firstly a method was optimised and developed in order to define a method of 
measuring oxidative stress in the airway epithelium. The effects of vitamin D on 
oxidative stress and antioxidant gene expression were then studied and possible 
mechanism of action were investigated using small molecule inhibitors of 
intracellular signalling pathways.  
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 5.2  Aims 
 Develop and optimise an assay in order to measure oxidative stress in 
airway epithelial cells 
 Study the effects of vitamin D on oxidative stress in airway epithelial cells 
 Study the effects of vitamin D on antioxidant gene expression in airway 
epithelial cells and its mechanism of action 
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5.3 Results 
 
In order to study the effects of vitamin D on oxidative stress in airway epithelial 
cells it was first necessary to optimise methodology for measuring ROS production. 
Various methods have been employed in the literature in order to study ROS 
production in different cellular systems but most rely on detecting specific oxidative 
species (269). The compound 2, 7’-dichlorodihydrofluoresceindiacetate (H2DCFDA) 
was first used in the literature as a method of measuring production of H2O2. 
However, since then it has been found to be reactive to many different radicals and 
therefore is now used as a measure of oxidative stress within cells (270). H2DCFDA 
crosses the cell membrane and is hydrolysed by cellular esterases to a non 
fluorescent intermediate which in the presence of ROS, is oxidised to highly 
fluorescent dichlorofluorescein (DCF). Intracellular DCF fluorescence can be 
quantified as a measure of overall oxidative stress within cells (270).  The emitted 
fluorescence is directly proportional to the concentration of reactive oxygen 
species. Many different methods have been described using this agent and these 
depend on the hypothesis tested and cell types used with each optimised for 
experimental outcome. H2DCFDA has been used predominantly by flow cytometry 
to measure ROS but more recently microplate and fluorescence microscopy 
methods have been developed (Table 5.1). In this study adherent cells were used 
and trypsinisation of cells into suspension for analysis can potentially change the 
oxidative state of the cells and therefore the subsequent results (271). With a 
microplate assay you can get a quantitative measurement of fluorescence intensity 
from the cells in situ and this also allows for a more high-throughput investigation. 
Table 5.1 summarises the studies which have used this agent with all the variables 
examined. These include the concentration of H2DCFDA to use on the cells, the 
length of incubation with the agent, the loading buffer, whether the cells are 
loaded with H2DCFDA before or after the stimulus, at what time point the 
fluorescence is measured, any recovery period from the cell loading, wash steps 
and also the method of quantitative analysis. 
 
 
 
 
 
 136 
5.3.1 Optimisation of methodology for the ROS assay  
A number of studies have measured ROS production using H2DCFDA in A549 cells 
(Table 5.1) therefore A549 were used initially to optimise the conditions for the 
experiment before testing out on the other cell types. From the literature, the 
concentration of 10 μM H2DCFDA was the most common concentration used and 
had been used previously in the A549. This dose was not found to be cytotoxic to 
the cells (Appendix Figure 7.4) 
Firstly it was necessary to test the basal fluorescence of the loading agent 
PBS/media in this assay. Phenol red found in the media can quench fluorescence, 
and media itself can interact with the H2DFCDA reagent 
(289) and therefore controls 
were included of media alone with the agent and cells alone in media with the 
reagent as a baseline. As shown in Figure 5.1, the media alone gave a much higher 
background fluorescence than the PBS when read under the same conditions and 
gain parameters on the microplate reader. Also, when media alone was incubated 
with H2O2 and H2DCFDA there was a non-significant increase in fluorescence not 
found with PBS (Figure 5.1 A). 
From optimising experiments for loading buffers, it was found that using a phenol 
red free media gave much lower background fluorescence than regular media 
making it almost the same as the PBS (data not shown). This was a better 
alternative to PBS, avoiding any stress from lack of nutrients, for longer 
experiments. 
H2O2 is increased in the sputum of patients with COPD and is also detected at 
higher levels in the exhaled breath condensate in these patients than control 
patients (64). H2O2 was used as a positive control as a known ROS inducer but is also 
a physiologically relevant stimulus. The next determinant was whether or not the 
cells should be loaded before the ROS inducing stimulus, as previous studies have 
used both methods (Table 5.1). Cells were either stimulated with 200 μM H2O2 for 
15 minutes before loading with 10 μM H2DCFDA for 15 minutes or vice versa (Figure 
5.1B and C). H2O2 significantly induced (p<0.05) ROS in cells with media when 
stimulated before loading (Figure 5.1B). However, there was a greater significant 
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effect of ROS induction by H2O2 in cells loaded before stimulation with PBS 
(p<0.001) (Figure 5.1C). 
Final optimisation experiments found that the optimal conditions were to load the 
cells with H2DCFDA for 40 minutes followed by a 20 minute cell recovery period 
before treatment with the ROS inducer. This was because some of the cell types 
were found to change morphology on loading with H2DCFDA but when the 
H2DCFDA was removed and replaced with media, cells recovered after 20 minutes 
to their original phenotype. This was not down to any cytotoxic effect on the cells 
(Appendix Figure 7.4).  
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5.3.2 Induction of ROS by  H2O2 and tBHP 
After optimising the conditions for the assay it was then necessary to determine 
how the fluorescence intensity would be measured. Some studies use one 
measurement at a certain time point but in this study the fluorescence change over 
time was measured in order to see the rate of change. As there was no literature on 
which time point to use, in this study the fluorescence change over time was 
measured. Any minor change in fluorescence values for the control wells of cells 
with the H2DCFDA was substracted from all the values. Tert-butyl hydroperoxide 
(tBHP) is a pro-oxidant hepatotoxic compound used as a model to study mechanism 
of cellular alterations arising from free radical action (290). In order to determine that 
the assay was sensitive to changes in fluorescence, the H2O2 or tBHP were added to 
the cells at different concentrations to determine if the assay could detect a dose 
dependent effect.  
Treatment of A549, NCI-H292 with 100-200 μM and 16HBE14o- cells with 200-400 
μM H2O2 and 100-200 μM tBHP gave a significant dose dependent induction of ROS 
for all except tBHP in the 16HBE14o- cells (Figure 5.2). 
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5.3.3 Effect of vitamin D on ROS production in airway epithelial cells 
Using the same parameters set up for the ROS producers, the effect of vitamin D 
alone on ROS production in the different airway epithelial cells was measured over 
time (Figure 5.3). Although there was a trend of an increase in ROS production after 
vitamin D treatment for 3 hours, the fluorescence intensity values were very low 
and variable and were not found to give a significant induction for any of the cell 
types. 
 141 
 
 
5.3.4 Effect of vitamin D on the induction of ROS by H2O2 and tBHP 
Vitamin D has been shown to sensitise breast and colon cancer cells to ROS 
dependent cytotoxicity induced by H2O2 
(266, 267) and also to protect normal prostate 
cells from oxidative stress induced death but not malignant prostate cells (268). 
To look at whether vitamin D exhibited redox activity in airway epithelial cells, the 
effect of vitamin D on the induction of ROS by H2O2 and tBHP was investigated. In 
chapter 4, vitamin D gave differing effects on cytokine production in different 
airway epithelial cells depending on whether the cells were pre-incubated for 1 
hour or 16-24 hours with vitamin D. Therefore, A549 and NCI-H292 cells were 
preincubated with vitamin D for 1 or 16 hours before loading the cells with 
H2DCFDA and then stimulating with H2O2 or tBHP. As shown in Figure 5.4, pre-
incubation with vitamin D had no significant effect on the induction of ROS by H2O2 
except in the A549 when pre-incubation for 1 hour with 10 nM vitamin D 
significantly decreased oxidative stress (p<0.001). 
 142 
 
 
In contrast, pre-incubation of NCI-H292 for 1 hour with 10 nM vitamin D prior to 
tBHP stimulation led to a synergistic induction of ROS (p<0.001) (Figure 5.5). 
 
 
 143 
 
 
As 1 hour pre-incubation of vitamin D was the only time point found to have a 
significant effect on ROS induction in the A549 and NCI-H292 cells, this was used for 
further study in the 16HBE14o- cells, shown in Figure 5.6. Firstly the effect of 1 hour 
pre-incubation with 10 and 100 nM vitamin D before either 200 or 400 μM H2O2 
was studied to see if there was a dose dependent effect for both. 100 nM vitamin D 
significantly increased 200 or 400 μM H2O2 induction of ROS (p<0.01) (Figure 5.6 A-
B). 
The effect of co-incubation of vitamin D and H2O2 treatment on ROS production 
was also examined in 16HBE14o- cells. 10 nM vitamin D co-incubated with either 
200 or 400 μM H2O2 gave a significant induction of ROS when compared to H2O2 
alone. With 200 μM, 100 nM vitamin D significantly induced ROS when compared 
with H2O2 alone, but was not as potent as 10 nM vitamin D (Figure 5.6 C-D) 
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Vitamin D was also added 30 minutes after 400 μM H2O2 to see if it would have any 
effect on the induction of ROS. Addition of 10 nM vitamin D gave a trend of an 
increase in ROS induction; however this was not significant (Figure 5.6 E). 
Finally, the effect of vitamin D pre-incubation on induction of ROS by 200 μM tBHP 
was studied. Vitamin D pre-incubation had no significant effect on the induction of 
ROS although there was a trend of a decrease in ROS production (Figure 5.6 F). 
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5.3.5 Effect of vitamin D on genes controlled by the antioxidant response 
element 
In chapter 4 section 4.3.13, vitamin D gave a biphasic response of cytokine 
production in the NCI-H292 cells, with longer incubation giving an induction of pro-
inflammatory cytokines. Vitamin D was also shown to have a pro-oxidant effect in 
the NCI-H292 with pre-incubation on tBHP treatment. It was hypothesised that 
vitamin D may also modulate the expression of antioxidant genes either by acting 
as a pro-oxidant itself or acting in an anti-oxidant way to increase antioxidant 
genes. The effect of vitamin D treatment on the expression of genes involved in 
antioxidant responses was studied. Genes investigated were NQO1, a phase II 
detoxifying enzyme contributing to xenobiotic detoxification, HO-1 and Ferritin H 
(cytoprotective stress response proteins) and Nrf2, the transcription factor that 
regulates the expression of a wide range of antioxidant genes (67, 199). 100 nM 
vitamin D treatment did not significantly affect expression of antioxidant genes in 
SAEC (Figure 5.7). However, in the NCI-H292 cells treatment with 100 nM vitamin D 
for 24 hours significant increased HO-1, ferritin H and Nrf2 mRNA expression. 
The expression of these mediators is regulated by the transcription factor Nrf2. This 
protein activates critical cellular pathways that protect against oxidative injury and 
inflammation. Vitamin D also caused a time dependent increase in Nrf2 protein, 
measured by western blot analysis (Figure 5.8).  
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5.3.6  Effects of molecular inhibitors on induction of antioxidant genes in NCI-H292 
by vitamin D treatment 
In order to determine the mechanism of how vitamin D might be inducing HO-1 and 
ferritin H mRNA expression, inhibitors were used to block different intracellular 
signalling pathways. 
Nrf2 is continually targeted for proteasomal degradation by its cytosolic inhibitor, 
Keap1. As a result, MG132 should cause a build up of Nrf2 in the cell, and 
subsequently an increase in the expression of its target genes. MG132 was used as 
a positive control in this study. Pre-treatment of cells with MG132 for 30 min alone 
or prior to 24 hr treatment with vitamin D significantly induced HO-1 mRNA 
expression (Figure 5.9 B). 
Y-27632 (a ROCK inhibitor) significantly reduced HO-1 basal expression but not 
vitamin D-induced expression, suggesting that vitamin D – induced HO-1 does not 
require ROCK (Figure 5.9A). Inhibiting PI3K had no effect on vitamin D – induced 
HO-1 mRNA expression with there still being a significant induction suggesting this 
pathway is not involved. However, inhibition of p38 MAPK, MAPKK, and JNK 
showed a similar effect to the positive control blocking the significant induction of 
HO-1 mRNA expression by vitamin D. This suggests that vitamin D could be 
modulating these pathways, or that the increase of HO-1 by these inhibitors is 
greater than the effect of vitamin D and therefore vitamin D is not able to increase 
the expression any further. 
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Treatment of cells with vitamin D significantly induced ferritin H mRNA expression 
(p<0.05) (Figure 5.10). As seen with HO-1, treatment with the positive control 
MG132  significantly increased ferritin H mRNA expression (Figure 5.11B).  
Treatment with the JNK, PI3K, p38 MAPK and MAPKK inhibitors in combination with 
vitamin D still gave an increase in Ferritin H expression which was significant with 
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some of the inhibitors. This suggests that vitamin D is not modulating these 
pathways to increase Ferritin H expression although further study is required to 
confirm this. 
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5.4  Discussion  
The novel findings of this study were that vitamin D modulated oxidative stress in 
different ways in the different cells and was found to significantly induce HO-1 and 
Ferritin H antioxidant response genes and increase Nrf2 protein expression in the 
NCI-H292 cells. Methodology was development and optimisation to study and 
compare oxidative stress in the different airway epithelial cells. 
To my knowledge this is the first study to use H2DCFDA by microplate assay to study 
oxidative stress in different airway epithelial cells. A number of variables were 
tested and optimised in the methodology to produce an efficient, reproducible 
technique allowing high throughput screening. H2O2 and tBHP are known inducers 
of oxidative stress and significantly modulated ROS production in a dose dependent 
manner, giving strength to the methodology of the assay. Although H2O2 is a 
physiologically relevant stimulus being found in greater concentrations in the 
exhaled breath condensate of patients with COPD, a limitation to the study is that 
the concentrations used were not physiologically relevant, but were ones that have 
previously been used in the literature to induce oxidative stress. In patients with 
acute exacerbations of chronic obstructive pulmonary disease levels of hydrogen 
peroxide in exhaled breath condensate has been found to be up to 3040 nM which 
is less than the 400 μM we used (291). However there is evidence to suggest that 
H2O2 in alveolar lining fluid can be 5 x 10
4 times greater than that of exhaled H2O2 
but is balanced out by antioxidants (291), so it is possible that airway epithelial cells 
do come into contact with much higher concentrations of H2O2 such as those used 
in this study (292). 
 
Vitamin D did not significantly affect ROS production alone. It could be that the 
effect of vitamin D alone is very small and possibly undetectable by this method. 
However, the assay was sensitive enough to detect differences in dose of ROS 
inducers and also the effects of vitamin D on ROS induction.  
In this study 1 hour of 10 nM vitamin D pretreatment reduced oxidative stress 
induced by H2O2 in A549 cells, and increased ROS induced by tBHP in NCI-H292 
cells. The latter fits in with literature on vitamin D sensitising breast, colon and 
prostate cancer cells to ROS induced injury or cell death therefore increasing ROS. 
However, the former was unexpected especially with effects only seen with the 
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lower dose of vitamin D and in the cell type most resistant to vitamin D treatment. 
The 1 hour time point is unlikely to be a genomic response but more a rapid 
response to vitamin D treatment which gives an anti-oxidant action. This effect 
might involve binding to the newly characterised 1,25-MARRS receptor which is 
known to have thioredoxin like sites and has been thought to participate in the 
mechanisms of cell protection against oxidative stress (293). Although A549 express 
high levels of Nrf2 in comparison to NCI-H292 cells (294) both cell types had a similar 
induction of ROS in response to H2O2 and tBHP. A recent study has shown that 
vitamin D reduced endogenous oxidants in lymphocytes but not in A549 cells (254). 
In contrast to Bo-Ying et al who reported that vitamin D protects normal prostate 
cells from oxidant induced damage, vitamin D synergistically increased ROS when 
pre-incubated, co-incubated and post incubated with H2O2 in the 16HBE14o- cells 
(295). This effect was found at both doses of H2O2 used. Interestingly, the effects of 
vitamin D pre-incubation were greater at the 100 nM of vitamin D, however the co-
incubation and post-incubation was greater only at the 10 nM vitamin D. These 
results are difficult to explain as it might be expected that if vitamin D is having a 
pro-oxidant effect, then the highest concentration of vitamin D used will give the 
greatest effect. This again highlights the different effects of vitamin D in the 
different airway epithelial cells and needs further investigation. 
To further determine the role of vitamin D in oxidative stress, the effect of vitamin 
D on the expression of anti-oxidant genes was investigated. Treatment with vitamin 
D had no effect on expression of antioxidant genes in the SAEC, however it induced 
HO-1 and ferritin H mRNA expression after 24 hours of treatment in the NCI-H292 
cells. Anti-oxidants such as sulforaphane increase Nrf2 expression and thus the 
expression of anti-oxidant genes, however these are also increased by pro-
inflammatory stimuli such as TNFα and LPS. Therefore this still does not 
conclusively say whether vitamin D is acting in a pro-oxidant or anti-oxidant nature 
in the NCI-H292 cells. Nrf2 is the main transcription factor controlling the 
expression of antioxidant expression and was found to be increased by vitamin D 
treatment at the protein level at 8 hours which would be conducive to activation of 
the mRNA of the other genes at 16-24 hours. Nrf2 mRNA expression was also found 
to be increased but at a later time point than the protein. Nrf2 has been shown to 
regulate its own transcription and also agents can change Nrf2 expression by 
 152 
stabilisation of the Nrf2 protein rather than changing mRNA which is possibly how 
vitamin D is working in this case (296). Previously in Chapter 4 section 4.3.5, it was 
found that vitamin D also increased TNFα expression in the NCI-H292 cells but this 
was also at 24 hours of treatment and therefore could not be what was driving the 
anti-oxidant response. It is clear that vitamin D is activating a pathway that is then 
driving a pro-inflammatory and possibly pro-oxidant effect in this cell type. 
To see which molecular pathways vitamin D was activating in this cell type in order 
to get the expression of HO-1 and Ferritin H, molecular inhibitors were used. 
Inhibiting the proteasome leads to stabilisation of Nrf2 and therefore would 
increase the expression of Nrf2 related genes (297). However the MAPK and PI3K 
phosphorylation pathways have also been implicated in the regulation of Nrf2, 
although this is predominantly in its activation. 
Using the inhibitors no pathways were found to be responsible for vitamin D 
increasing the expression of HO-1 and Ferritin H mRNA exrepssion but again this 
data was variable and would need further investigation to confirm this. 
In this study HO-1 and ferritin H were activated by vitamin D but the other Nrf2 -
regulated gene NQO-1 was not. HO-1 participates in generating the antioxidants 
carbon monoxide and bilirubin. The activation of ferritin sequesters iron which is 
the product of HO-1 catalysis and therefore the induction of both leads to an 
antioxidant state. Although NQO-1 is one of the most robust responders to Nrf2 
activation it was not induced by vitamin D in this study. It appears vitamin D was 
increasing the expression of proteins which have antioxidant properties rather than 
those involved in xenobiotic metabolism (297). 
The strengths of this study is that the ROS assay developed was robust, gave 
reproducible data with tight error bars and was sensitive enough to detect a dose 
dependent effect and also the effect of vitamin D. One limitation is that no control 
anti-oxidant was used such as NAC to block the induction of ROS to show that the 
assay was sensitive enough to detect changes in antioxidants, although significant 
changes were detected with 1,25(OH)2D3 treatment. There is also evidence in the 
literature to suggest that the compound H2DCFDA is not completely stable and in 
some cell types has been shown to leak out of the cell (269, 271, 298). Therefore, with a 
microplate based assay where not only cellular fluorescence but also buffer 
fluorescence is measured then cellular leakage would affect the results. This was 
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controlled for as much as possible with the cells with H2DCFDA taken as control 
with any change in fluorescence removed from the other values, although this 
effect was found to be minimal. However, one cannot rule out that H2DCFDA could 
have leaked out of cells and some of the fluorescence was from the buffer. 
Therefore any effects seen of vitamin D could be that it increases or decreases 
leakage of H2DCFDA from the cells. This could be improved in the future by using a 
more stable derivative of H2DCFDA such as CM-H2DCFDA which has an increased 
cellular retention. In addition, the media could be removed at the end of the 
experiment and then read on the microplate reader so that any fluorescence of the 
media could be removed and therefore only cellular fluorescence is measured. 
In this study the protein expression for the antioxidant genes could have been 
measured to strengthen the current data. Equally the protein should have been 
quantified before gel loading so that the western blot data could be quantified as β 
actin can also change over time. Although vitamin D was shown to increase Nrf2 
protein expression and also activate HO-1 and Ferritin H mRNA which are genes 
controlled by Nrf2, one cannot rule out that these could be independent events and 
further study should look at silencing Nrf2 to see if these effects are still seen.  
 
5.5  Conclusion 
Vitamin D modulates oxidative stress in different ways in the different airway 
epithelial cells. In the NCI-H292 cell line vitamin D was found to induce the 
expression of Nrf2 and anti-oxidant genes. Further study is required to fully 
determine the mechanism of action of vitamin D and whether its action is due to 
being an anti-oxidant or pro-oxidant. Different effects might occur under different 
conditions and concentrations of vitamin D. 
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Chapter 6: 
 
General discussion and future studies 
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6.1  Airway epithelial cells and lung inflammation 
COPD is both driven and exacerbated by inflammatory responses which with 
oxidative stress form a vicious circle generating excessive inflammation and 
irreversible damage to the airways. With cigarette smoke exposure being the 
largest contributing factor to COPD development (199), many studies have focussed 
on cigarette smoke induced damage. However, not all smokers develop COPD (3) 
and another contributing factor for disease progression is exacerbations due to 
infection (12). One of the main pathogens causing exacerbation is Pseudomonas 
aeruginosa whose LPS was used to initiate inflammatory responses in this study (10-
12). TNFα is also a key cytokine contributing to this disease which is found in 
increasing concentrations in the sputum and BAL of patients with COPD, and which 
can induce both local and systemic effects (3, 7, 199). It is often written that the major 
cell type responsible for COPD pathology is the neutrophil (74). However, the airway 
epithelium is the first contact to noxious substances and pathogens entering the 
lung and responds by the production and release of cytokines for the recruitment of 
inflammatory cells. Therefore they play a crucial role in the initiation and extension 
of the inflammatory response and contribute to the disease.  
 
In this study the cell types chosen were those that have been widely used to study 
airway inflammation; A549, NCI-H292 and 16HBE14o- along with primary small 
airway epithelial cells. These were characterised by determining the basal 
expression of different mediators. A summary of the similarities and differences 
between the difference cell types and conclusions is shown in table 6.1. Key 
mediators found to be expressed at mRNA level were IL1β, IL-6, IL-8, TNFα, ICAM1, 
MMP-9 and MUC5AC and at the protein level were IL-6, IL-8, MMP9 and MUC5AC. 
This is the first study to compare each of these cell types which were found to 
express very similar mediators. LPS and TNFα were used to activate an immune 
response to see what mediators were induced which might indicate how the airway 
epithelial cells contribute to COPD pathology. Key mediators found to be induced 
were IL-6, IL-8, and MUC5AC. Comparisons were made of the basal expression and 
kinetic induction of mediators in the different cell types but further study should 
compare the expression of receptors TLR4 and TNFR1 to determine if this explains 
any differences in expression patterns found. Equally the cells in this study were 
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cultured in 2D and further study in 3D air liquid interface would be useful to 
compare cell types. For example, mucin expression is likely to be different in 3D 
culture especially in the homogeneous SAEC where 3D culture would allow 
differentiation into goblet cells and subsequent mucin expression. Other studies 
could look at further MMPs and also look at the expression of TIMPs in the airway 
epithelium. 
These results emphasise that investigators should validate that their chosen cell line 
is appropriate by checking that it performs in a similar manner under the assay 
conditions used to primary cells. 
 
Another area of potential investigation derived from this study is to look into the 
induction of mediators by LPS from different pathogens and in different tissues to 
test the hypothesis that epithelial cells from different tissues respond differently to 
the same variant of LPS. 
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6.2  Vitamin D and lung inflammation 
Vitamin D is now widely accepted as an immunomodulatory agent that has been 
shown to have many functions. Vitamin D deficiency has been shown to be 
associated with an increased risk of respiratory tract infections, tuberculosis (85) and 
impaired lung function (125, 127). Despite this, very little has been investigated on the 
effects of vitamin D in airway epithelial cells. More recently, groups have 
established that airway epithelial cells constitutively express CYP27 suggesting they 
are responsive to vitamin D treatment (123) and vitamin D has been shown to 
modulate inflammatory responses to respiratory synctial virus infection (249). 
Dysregulation of the vitamin D signalling pathway has also been implicated in lung 
cancer with increased expression of CYP24 in cells from these patients as well as 
reduced CYP27 and VDR (178-180, 252). All of these together point to the fact that 
vitamin D could be a very important modulator in the lungs and requires further 
investigation. 
 
This is the first study to investigate the effect of vitamin D in a wide range of airway 
epithelial cells looking specifically at modulation of agents which are important in 
the pathology of COPD. This study demonstrated vitamin D to have a number of 
different effects which were cell type dependent as shown in table 6.1. IL-6 was a 
key cytokine found to be modulated in the SAEC, 16HBE14o- and NCI-H292 cells. 
This cytokine is important in the initiation and extension of the immune response. 
MUC5AC is another important mediator involved in airway obstruction which was 
found to be modulated by vitamin D treatment with reduced expression at both the 
mRNA and protein level in the NCI-H292 cells. MMP9 was interestingly reduced in 
the 16HBE14o- cells but in the SAEC was reduced at the mRNA level but increased 
at the protein level.  The 1,25-MARRS is important in packaging processes in the ER 
and is also involved in signalling at the cell membrane. In chondrocytes, vitamin D 
causes release of MMP9 from extracellular matrix vesicle organelles into the ECM 
by binding to the 1,25MARRs. Vitamin D is also involved in the activation of MMPs 
from their inactive zymogen form (262). Therefore a possible hypothesis from this is 
that in the SAEC vitamin D could be causing release of ‘ready made’ MMP9 from 
vesicles by binding to 1,25MARRS or it may be causing activation of MMP9 which 
has already been secreted as only active MMP9 is picked up by gelatin zymography. 
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This area is certainly interesting and requires further investigation. One way to 
investigate this would be to block the 1,25-MARRS to see if it prevents the increase 
in MMP9 activity. However, it does not explain why a different effect was found in 
the 16HBE14o- cells. 
 
The concentration of vitamin D used in this study was higher than physiological 
levels and therefore was more a therapeutic dose. However, as yet no-one has 
determined how much active vitamin D is produced within the lung given adequate 
serum levels of 25(OH)D3. The in vivo concentrations of active vitamin D generated 
in tissue is currently an area of interest for a number of researchers some of which 
are looking at prostate tissue of patients supplemented with vitamin D to 
determine how much active vitamin D is produced. This area has been quite under-
researched though this is mainly due to discrepancies on how to measure vitamin D 
levels accurately due to the assays detecting its different epimers and metabolites 
(299). It would be very interesting to look at how much active vitamin D is produced 
within the lung.  
 
The mechanistic data in this study needs further work to show what signalling 
pathways vitamin D is activating / modulating in airway epithelial cells. This could 
be done a number of ways but for a comprehensive approach would need to study 
changes in the level of protein expression and phosphorylation status of different 
signalling components at various time points after vitamin D treatment. 
 
6.3  Vitamin D and oxidative stress  
Oxidative stress is key to driving inflammation in COPD and is mainly caused by 
smoking. A number of different methodologies have been used to study oxidative 
stress but these rely on the detection of specific species whereas the H2DCFDA 
assay developed in this study allowed high throughput screening and reproducible 
results. Future studies should further develop this assay with more stable reagents 
in order to screen potential oxidative stress inducers or antioxidants. Vitamin D has 
been shown to sensitise cancer cells to oxidative damage (266). In this study vitamin 
D was actually found to give a synergistic induction of ROS in the normal bronchial 
cells whereas literature has shown vitamin D to protect normal prostate cells from 
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oxidative injury (268). This again appears to be cell type dependent and it will be key 
to identify cellular characteristics which show similar vitamin D attributes so that an 
explanation for this can be established. 
 
Vitamin D was found to induce antioxidant gene expression and Nrf2 protein 
expression in the NCI-H292 cells. It was not found to be cytotoxic to the cells or 
significantly induce ROS and therefore did not appear to be pro-oxidant except 
when pre-treated before tBHP where there was found to be a synergistic effect of 
vitamin D. Vitamin D was also found to increase TNFα mRNA expression at the 
same time point as the anti-oxidant response genes. It appears vitamin D treatment 
is activating a late pro-inflammatory response and therefore also increasing anti-
oxidants at this time point. The reason for this still needs to be established. 
 
6.4  New hypotheses from this study to be investigated 
This study has identified novel mediators that vitamin D modulates in airway 
epithelial cells which may be important in disease pathology. It has also 
investigated the mechanisms involved in this although this requires further study. 
Initially the plan for this study was to include the effects of vitamin D in airway 
epithelial cells from patients who have COPD and this would still be important to 
study in the future to fully determine if vitamin D is beneficial in these diseased cell 
types. 
 
Oxidative stress has been shown to be important for the induction of MUC5AC in 
NCI-H292 cells as ROS are required to activate latent TNFα converting enzyme 
(TACE) exposing the catalytic domain to cleave pro-TGFα which is the ligand for 
EGFR, initiating a MAPK cascade leading to mucin gene expression and protein 
production (243). Nrf2 has been shown to block MUC5AC expression because it 
activates antioxidants blocking ROS production (300). Therefore in this study with 
vitamin D increasing Nrf2 and blocking MUC5AC expression in the NCI-H292 cells 
these two events could be a potential mechanism and would be interesting to study 
further. Also, the VDR has been shown to directly inhibit EGFR transcriptional 
activity in breast cancer cells which is augmented on 1,25(OH)2D3 treatment 
(301) 
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suggesting that this could also be a mechanism and therefore is a VDR dependent 
effect which would need further investigation. 
 
Taking into account vitamin D metabolism and the activation of CYP24 by vitamin D, 
these latter effects of induction of TNFα and antioxidant genes at 24 hours in the 
NCI-H292 cells could be due to early activation of signalling molecules by vitamin D 
or it could be that vitamin D is metabolised into its epimer or other metabolites 
which are then driving an inflammatory response. An important study would be to 
look at the metabolism of vitamin D in the different cell types studied to see the 
half life of active vitamin D and its metabolites and then whether any of these 
metabolites have a biological activity as has been found in some studies (302). 
The A549 cells appear insensitive to vitamin D treatment and this is likely to be due 
to over expression of CYP24, but it would be interesting to KO CYP24 to see if 
vitamin D can then modulate inflammatory mediators like the other cell types. As it 
has been shown recently that inhibiting CYP24 does increase the antiproliferative 
effect of vitamin D in these cells. 
 
Another area of vitamin D research is the rapid responses vs the genomic responses 
and both the time frame of these responses and whether they involve the 
1,25MARRs or VDR needs further investigation but these two different modes of 
action might be responsible for the effects we have seen at different time points. 
 
6.5 Human Studies 
As yet much of the data on the potential of vitamin D in COPD is speculative with 
many more molecular papers on its action showing anti-inflammatory, anti-
protease and anti-bacteria properties all of which would be beneficial to COPD 
pathology (303). Higher vitamin D levels have been associated with improved lung 
function (125), and vitamin D deficiency is found in many COPD patients and 
correlates with disease severity (248). However, studies have also shown that in 
patients with severe COPD, circulating 25(OH)D is not predictive of acute 
exacerbations of the disease (304) and that 25(OH)D levels are not associated with 
adult lung function (305). These discrepancies could be down to the genetics of the 
populations studied and it may be that subsets of patients with COPD are more 
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responsive to the effects of vitamin D, although much larger patient cohorts are 
required to get sufficient data in order to characterise these subsets. 
 
With vitamin D deficiency linked to COPD disease severity it is as yet unclear 
whether deficiency gives you higher risk of the disease or if more vitamin D is used 
up when you have the disease (187). It may be that vitamin D may play more of a 
preventative role than a possible therapeutic role but until clinical trials are carried 
out on vitamin D supplementation of patients with COPD and of control subjects 
and smokers to see if it reduces COPD development and / or modulates disease 
severity then this question will remain unanswered.  
 
It is clear that COPD patients are at an increased risk of getting osteoporosis and 
therefore vitamin D supplementation to give patients sufficient levels is an 
important step (187). COPD patients have a high rate of vitamin D deficiency and 
intervention studies are necessary to determine if vitamin D supplementation is of 
benefit in the prevention and treatment of osteoporosis in patients with COPD (306). 
 
There is no doubt that having a sufficient vitamin D status should be a goal for the 
whole population due to its broad range of health benefits that have been and 
continue to be found. However, as yet recommended levels of vitamin D have only 
been set for its skeletal actions, despite much evidence for other beneficial effects, 
and as such it is likely to be a long while before recommendations are set for 
vitamin D in lung disease as this is a somewhat under studied area. 
 
6.6  Conclusion 
As is the nature of research, this study brought about many more questions than it 
answered. However, it has identified novel mediators which are modulated by 
vitamin D in airway epithelial cells and are important in lung disease pathology. 
Further studies should investigate how vitamin D is modulating IL-6 and MUC5AC 
expression in airway epithelial cells and establish if vitamin D is beneficial in disease 
pathology using human studies. 
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APPENDIX I 
Cytotoxity data for reagents and 
inhibitors 
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Appendix II 
Buffers and Solutions
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Cell culture 
Fibronectin coating solution for 16HBE14o- cells 
 88 mL LHC basal medium, 10 mL 0.1% BSA, 1 mL vitrogen, 1 mL human fibronectin 
 
cDNA synthesis 
10 µl Reverse Transcription Reagents Mastermix 
RNA at 50 ng/µl 
10 µl reaction = 4.5 µl (RNA+H2O) + 5.5 µl Mastermix 
Number of 
Samples 
MgCl2  
(25 µM) 
10 x RT 
buffer 
dNTP RT RNase Random 
Hexamers 
1 x 2.5 µl x 1 µl x 1 µl x 0.25 µl x 0.25 µl x 0.5 µl 
 
Random hexamers were diluted ½ before use to 25 µM. 
qRT-PCR 
Polymerase Chain Reaction Reagent Mastermix 
20 µl PCR reaction = 5 µl cDNA + 15 µl Mastermix 
Number of 
Samples 
SYBR green H2O Primer (5 µM) 
forward + reverse 
1 x 10 µl x 4 µl x 1 µl 
 
Western blot  
1 x running buffer 
760 mL dH2O and 40 mL 20 X MOPS SDS running buffer 
 
1 x transfer buffer 
680 mL dH2O, 80 mL methanol, 40 mL 20 X transfer buffer, 1 mL anti-oxidant 
 
Blocker 
20 g Marvel and 400 mL TBST 
 
10 X TBST 
48.4 g tris base 
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160 g NaCl 
62 mL 5M HCl 
20 mL Tween-20 
pH to 7.6 
Dilute to 1L with distilled water 
 
Gelatin Zymography 
 
10% Resolving Gel (2plates) 
15 mg gelatine 
5.9 mL dH2O 
3.8 mL 1.5 M Tris pH 8.8 
5 mL 30% acrylamide: 0.8% bis-acrylamide 
150 µL 10% sodium dodecyl sulphate 
150 µL 10% ammonium persulphate (0.1 g in 1 mL dH2O) 
6  µL TEMED 
 
5% Stacking Gel (2 plates) 
2.75 mL dH2O 
0.5 mL 1 M Tris pH 6.8 
0.65 mL 30% acrylamide: 0.8% bis-acrylamide 
40 µL 10% sodium dodecyl sulphate 
40 µL 10% ammonium persulphate 
4 µL TEMED 
 
5 x running buffer (1L) 
15 g tris 
94 g glycine 
50 mL 10% SDS (10 g in 100 mL dH2O) 
Make up to 1L with dH2O 
 
Rinse buffer 
25 mL Triton-X100 
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Make up to 1 L with dH2O 
 
Incubation Buffer 
50 mM tris pH 7.5 (50 mL of 1 M Tris pH8 (24.22 g in 200 mL)) 
5 mM CaCl2 (5 mL 1 M CaCl2 (14.7 g in 100 mL)) 
Make up to 1L with dH2O 
 
4 x Loading buffer (50 mL) 
200 mM tris pH 6.8 (20 mL 1 M Tris pH 6.8) 
4% SDS (2g) 
0.1% bromophenol blue (50 mg) 
40% glycerol (20 mL) 
 
Coomassie Blue stain (200 mL) 
30% isopropanol (60 mL) 
10% acetic acid (20 mL) 
2.5 mg/mL coomassie brilliant blue R (0.5 g in 120 mL dH2O) 
 
Destain solution (200mL) 
10% isopropanol (20mL) 
10% acetic acid (20mL) 
160 mL dH2O 
 
EDTA 0.05M 
 
Immunostaining 
Gelatin quench buffer 
1 g gelatin in 450 mL H2O 
50 mL 10 x PBS 
 
Blocking buffer 
15 mL normal goat serum 
35 mL gelatin quench buffer 
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Wash buffer 
500 mL PBS 
30 mL 10% goat serum/PBS 
10 mL goat serum 
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APPENDIX III 
 
Dissociation curves and standard 
curves for SYBR green qRT-PCR 
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IL1β 
GAPDH 
CYP24 
Dissociation curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL6 
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VDR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MMP1 
Ferritin H 
MUC5AC 
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TNFα 
IL8 
Nrf2 
MMP9 
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ICAM1 
 
TGFβ 
MMP12 
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Standard curve efficiencies 
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APPENDIX IV 
 
Standard curves for flow cytometric 
bead array 
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